DolceraWiki - User contributions [en]

Digestive Remedies Market in India and China

2010-08-06T09:09:50Z

Anand.shukla: /* Results */

=Market Overview=
==India==
* Digestive remedies in India saw current value growth of 7% in 2008, to reach Rs 8.5 billion
* Factors such as irregular eating habits, unhygienic food and stressful lifestyles have driven growth
* Digestive enzymes displayed the fastest growth, of 13% in current value terms, to reach Rs 1.7 billion
* GlaxoSmithKline Consumer Healthcare Ltd launched Eno Digesure in the first quarter of 2008
* Dabur India Ltd leads sales of digestive remedies, with a 26% value share, thanks largely to its Hajmola brand
* Sales of digestive remedies are predicted to grow by 17% in constant value terms over the forecast period[http://www.euromonitor.com/]

==China==

* Current value sales grow by 8% from 2007 to reach RMB3.8 billion in 2008
* Stressful and hectic lifestyles result in higher incidence of digestive problems
* Proton pump inhibitors see most dynamic current value growth of 14% in 2008
* Jilin Xiuzheng Pharmaceutical Co Ltd leads sales with 17% share of value sales in 2008
* Constant value CACR of 7% expected during forecast period[http://www.euromonitor.com/]

=Trends in Digestive remedies industry=

==India==

* Growth in digestive remedies in 2008 was led by urban consumers. Due to a growing economy and more hectic lifestyles, urban consumers increasingly skipped meals and ate out in sometimes unhygienic fast food outlets.
* Increasing stress led to constipation, diarrhoea and acidity, especially among young working adults. As a result, demand for digestive remedies was buoyant. In addition to this, lack of intake of nutrients in the form of fruits or dietary supplements further pushed growth.
* Heightened marketing activities by Dabur India Ltd for Hajmola drove digestive enzymes growth. Changes in positioning ensured that consumers perceived Hajmola as a must-have after every meal.
* For child-specific indigestion and heartburn remedies consumers started moving towards anti-spasmodic remedies.
* The value share of herbal/traditional products rose marginally in 2008, having declined in previous years. Dabur India Ltd continued to be the leading player in this area, with brands such as Hajmola and Pudin Hara.
* Due to the belief that standard/allopathic products have greater efficacy than their herbal/traditional counterparts, consumers generally prefer taking standard/allopathic products when it comes to treating severe bouts of acidity and other digestive ailments to get instant relief. However, consumers who take digestive remedies on a regular basis often prefer herbal/traditional products, due to their being less susceptible to side effects.
* Within indigestion remedies, the fastest growing type is digestive enzymes. Due to their positioning as a easy to take and without a medicinal taste, consumers are more comfortable using digestive enzymes on an everyday basis, unlike antacids which are positioned primarily as medicines. Hajmola’s tangy taste has endeared this brand to consumers from all age groups.
* Digestive ailments have risen, as consumers are rarely having a balanced diet, with regular intake of cereals, fruits or other dietary supplements. This trend has positively affected sales of antacids, digestive enzymes, laxatives and diarrhoeal remedies.
* UTC sales remained high in digestive remedies in 2008. Laxatives, diarrhoeal remedies, H2 blockers, motion sickness remedies and child specific products are where most UTC sales are seen. Brands such as Dulcolax, Cremaffin, Depandal and Stemetil enjoy long-standing brand loyalty, due to which they have virtually become household names and are freely sold without prescriptions.[http://www.euromonitor.com/]

==China==

* With rapid urbanisation and increasingly stressful lives, people developed increasingly irregular daily schedules. This trend was especially notable amongst the younger generation who increasingly live apart from their families.
* These consumers often have irregular meal times, which can cause digestive problems. For office workers, meanwhile, the time available for lunch is limited, with some being too busy to take lunch.
* Growth in digestive remedies in 2008 is slightly lower than in 2007. Many consumers became more health-conscious and adopted healthier diets, which led to a slowdown in growth for mature digestive remedies such as diarrhoeal remedies and laxatives. However, consumers’ growing confidence in selfmedicating with digestive remedies maintained good growth in 2008.
* Proton pump inhibitors saw the highest current value growth in 2008 over the previous year. These products are used for the prevention and treatment of acid-digestion conditions, such as ulcers and gastrooesophageal reflux disease (GERD).
* According to trade sources, GERD affects almost 7% of the population in China at some point. From a survey based on 7,000 GERD patients at the beginning of 2008, meanwhile, 70% of patients are aged 26-55-years-old. As proton pump inhibitors are more effective than traditional medicines and can relieve symptoms and heal the oesophageal lining for most who suffer from GERD, they became increasingly popular.
* Child-specific digestive remedies continued to see good growth in 2008. These products are influenced by very different factors than adult digestive remedies. Sales of adult digestive remedies are related mostly to consumers’ diets, stress levels and illness. Meanwhile, children’s digestive remedies saw sales boosted by parents purchasing decisions, with more parents opting for child-specific products for their children. These products offer fewer side-effects and are milder, with growing awareness of child-specific products resulting in them gaining popularity.
* Consumers also remain cautious about self-medication for children and prefer to take their children to a hospital for diagnosis in order to ensure their safety.
* Herbal/traditional products accounted for 22% of total value sales in digestive remedies in 2008, while standard products continue to dominate. Local consumers generally believe that herbal remedies are safe and good for long-term use, causing few side effects. This offers herbal/traditional products an advantage for some digestive diseases, which may need long-term care.
* For short-term digestive disorders and for rapid relief most prefer standard products as they believe standard products offer a more rapid effect.
* Most established herbal product in digestive remedies was Jiangzhong Pharmaceutical Co’s Jiangzhong in indigestion and heartburn remedies.
* IBS treatments are not available OTC. However, consumers can obtain these products via prescriptions or even under-the-counter (UTC) in some small pharmacies/drugstores. The UTC sales of IBS are however very small, as consumers prefer to seek medical advice for this long-term disorder from professionals.[http://www.euromonitor.com/]

==Competitive landscape==

==India==

* Dabur India Ltd led sales of digestive remedies in India in 2008. The company increased its value share to 26%, making it the fastest growing company in digestive remedies. Sales of Halmola were good while the sales of Pudin Hara were static due to an exceptionally short summer. The second placed manufacturer in 2008 was Abbott India Ltd, with its leading antacid brand, Digene.
* Sales of Cadila Healthcare Ltd, the marketer of best-selling laxative Dulcolax, have come under increasing pressure from the brand Duphalac, from Solvay Pharma Ltd. Consumers have shown a preference for lactulose-based brands, such as Duphalac, as they tend to be gentler on the stomach than bisacodyl-based brands, such as Dulcolax.
* Changing consumer preferences also led to sales of GlaxoSmithKline Pharmaceuticals Ltd and RPG Life Sciences Ltd in diarrhoeal remedies coming under pressure from Rx drugs, such as Cifran CT, from Ranbaxy Laboratories Ltd. Unlike brands such as Depandal, Lomotil and Lomofen, which simply provide relief from diarrhoea, drugs such as Cifran CT not only address diarrhoea in a patient, but also provide a more holistic benefit by working on the intestines and digestive system in general.
* Torrent Pharmaceuticals Ltd launched Fibotab in late 2007. The brand uses calcium polycarbophil as its API, and thus not only controls diarrhoea, but also treats constipation, thus making it a truly multipurpose drug. The brand has been positioned as better alternative to Isabgol.
* Novartis India ltd launched a new product Benefiber in 2008. A wheat dextrin-based laxative, the brand’s largest selling point is that it does not thicken and can be mixed with any beverage.
* Digestive remedies remained quite fragmented in 2008. Besides Dabur India Ltd and Abbott India Ltd, no other company managed to achieve a value share of more than 10%. Companies such as Pfizer Ltd, GlaxoSmithKline Pharmaceuticals Ltd and TTK Pharma Ltd lag behind with shares of around 4% to 5% each.
* Eno Digesure was launched by GlaxoSmithKline Consumer Healthcare Ltd in December 2007.[http://www.euromonitor.com/]

==China==

* Jilin Xiuzheng Pharmaceutical Co Ltd led digestive remedies with 17% value share in 2008. The company’s Si Da Shu brand is widely popular due to its clear product position and its differentiation of gastric diseases, offering variants for “stomach-ache”, “fullness” and “acid digestion”.
* Established local player Jiangzhong Pharmaceutical Co offers well-known herbal brand Jiangzhong Jian Wei Xiao Shi Pian in antiflatulents. In 2008, the company saw the biggest increase in value share in digestive remedies over the previous yea. Jian Wei Xiao Shi Pian is a generic traditional herbal remedy used to cure indigestion by easing stomach upsets and bloating.
* Domestic companies strived to gain share towards the end of the review period, benefiting from low prices and a wide distribution network.
* All of the leading domestic companies achieved GMP standards accreditation by the end of the review period, with product quality thus significantly improving.[http://www.euromonitor.com/]

=Digestive remedies category size and growth=

[[Image:Overall Digestive remedies market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese market is more then double of the Indian market and is expected to grow at a CAGR of 6.6%.
*While,Indian market will continue to grow at 3.1% on CAGR basis.
[[Image:Dihoral Remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese diarrhoeal remedies market is more then triple of the Indian market and is expected to grow at a CAGR of 5.6%.
*While,Indian market will continue to grow at 1.8% on CAGR basis.
[[Image:Indigestion and Heart Burn Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese Indigestion and heartburn remedies market is expected to grow at a CAGR of 6.9%.
*While,Indian market will continue to grow at 3.8% on CAGR basis.
[[Image:Motion Sickness Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese motion sickness remedies market is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.
[[Image:Child specific digestive remedies.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese child specific digestive remedies is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.

==Forecasted Sales of Digestive Remedies==

[[Image:Forecasted figures for Digestive remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
 
[[Image:Forecasted figures for CAGR 0813.jpg|center|thumb|500px|Source:Euromonitor]]

=Top digestive remedies companies and brands=
==India==
[[Image:india digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:india digestive brands1.jpg|center|thumb|500px|Source:Euromonitor]]

==China==
[[Image:china digestive brands.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:china digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
=Herbal vs Standard digestive remedies=
===India===
[[Image:india herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]
===China===
[[Image:china herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]

=Prevalence of Digestive Diseases in India and China=
===India===
[[Image:Divespive prevalence india.jpg|center|thumb|500px|Source:Cureresearch.com]]

===China===
[[Image:digestive prevalence china.jpg|center|thumb|500px|Source:Cureresearch.com]]

=Probiotics=

==Probiotics Market in India and China==

===Methodology===
[[Image:Probiotioc market estimation methodology1.jpg|thumb|500px|center|Methodology]]

===Results===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|'''Country'''
|align = "center"|'''Compared Geography'''
|align = "center"|'''Probiotic Market in Mn $'''
|align = "center"|'''Population 2008 in Thousands'''
|align = "center"|'''Per Capita Probiotic Consumption (in $)'''
|align = "center"|'''PPP Adjustment Factor'''
|align = "center"|'''PPP Adjusted Consumption Per Capita in ($)'''
|align = "center"|'''Households with high Disposable Income (in thousands)'''
|align = "center"|'''Average number of people per household'''
|align = "center"|'''Potential Market for Probiotics (in Mn $)'''
|-
|align = "center" rowspan = "3"|'''India'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|2.73
|align = "center"|1.84
|align = "center" rowspan = "3"|4466.70
|align = "center" rowspan = "3"|5
|align = "center"|41.16
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.42
|align = "center"|3.40
|align = "center"|75.84
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|4.21
|align = "center"|3.54
|align = "center"|79.17
|-
|align = "center" rowspan = "3"|'''China'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|1.83
|align = "center"|2.75
|align = "center" rowspan = "3"|23163.9
|align = "center" rowspan = "3"|4
|align = "center"|254.77
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.01
|align = "center"|3.85
|align = "center"|356.71
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|2.82
|align = "center"|5.29
|align = "center"|490.50
|-
|}

*The households that are wealthy enough to consume such products on a regular basis are take as those having disposable income more then 15000$ per year.

=Product Dashboard=
[[Image:Digestive Product Dashboard.jpg|center|thumb|500px]]
* The product dashboard contains the names, effect and claims of various digestive remedies available in Indian and Chinese markets.[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=664 Click here] to view the dashboard.

=Prospects of digestive remedies industry=

===India===

* Increasingly busy lifestyles, irregular eating habits, lack of exercise and poor nutrition in meals will continue to be the main drivers of growth in sales of digestive remedies over the forecast period.
* Digestive problems such as constipation and acidity are likely to rise. In addition to this, lack of basic amenities, such as clean water and sanitary conditions in many rural and semi-urban parts of India, will give further impetus to growth, as these are the main causes of diarrhoea.
* The forecast period is expected to see growth a lot higher than that of the review period in constant value terms.
* Growth will be driven by increasing UTC consumption of proton pump inhibitors, antiflatulents, IBS treatments and H2 blockers. Consumers are expected to turn to advanced drugs like these in the hope of getting faster and long lasting relief from various digestive ailments.
* In the short term, growth in 2009 is expected to be marginally stronger than that in 2008, in spite of the economic downturn in India. Consumption of digestive remedies is expected to increase in line with a rise in population, which will naturally widen the consumer base.
* The review period saw many yoga centres being established in urban centres. Yoga is frequently touted as an effective way to control digestive ailments. If a “yoga revolution” does sweep across the country, growth in digestive remedies will again be negatively affected.
* Digestive enzymes are set to see the strongest growth over the forecast period, of 53% in constant value terms. Growth will be driven to a significant extent by Dabur India Ltd increasing penetration through aggressive marketing and promotional activities. Child-specific indigestion and heartburn remedies are expected to see the slowest growth between 2008 and 2013, of just 5% in constant value terms.
* Fibotab is expected to perform extremely well in the short term. The brand is expected to see success based on its multipurpose positioning as well as the fact that it does not need to be mixed with water, unlike Isabgol. On the other hand, Benefiber is not expected to do well, because of its high price and a lack of promotion by Novartis India Ltd.
* Companies might opt to position their products as meal supplements, instead of medicines, to take advantage of the growing trend to consume digestive remedies on a regular basis. Furthermore, companies will look to rural areas to drive further growth in sales, as urban areas are highly saturated when it comes to products such as antacids, diarrhoeal remedies and laxatives. Promotional activities are likely to include tying up with additional distributors, and conducting road shows and awareness programmes.[http://www.euromonitor.com/]

===China===

* Digestive remedies are expected to post moderate growth in most product areas during the forecast period. The continued acceleration of consumer lifestyles is expected to lead to an increasing number of people skipping meals or having irregular meal times. This will be the main factor maintaining demand for digestive remedies during the forecast period.
* Healthy eating and the widening use of vitamins and dietary supplements might pose a threat to digestive remedies during the forecast period. Sales of functional food products with high fibre content are expected to increase during the forecast period, while food containing prebiotics and/or probiotics such as yoghurt is also expected to see growing sales. These products can aid digestion and may reduce the incidence of digestive disorders.
* Moreover, consumers are increasingly opting for natural food instead of medicine under prevailing health trends. As a result, sales of diarrhoeal remedies are likely to be adversely affected.
* The decreasing demand for motion sickness remedies was led by the advancement of local transportation infrastructure. Moreover, the unit price of motion sickness remedies is low, at around RMB0.1 per tablet in 2008, with low prices also constraining value sales.
* Sales of motion sickness remedies are likely to remain sluggish during the forecast period, despite an increasing number of frequent travellers. This is because growth in the number of travellers is expected to mostly come from students and young adults. Many people in these groups do not bother taking motion sickness remedies and are often more accustomed to the discomfort caused by vehicle motion.
* Proton pump inhibitors is expected to see the fastest constant value growth in digestive remedies over the forecast period. Robust sales growth for the leading brand, AstraZeneca China Pharm Co Ltd’s Losec Mups, are likely to attract local manufacturers and other international brands, with new players thus set to enter this product area.
* As in other product areas of OTC healthcare, the unit price of digestive remedies is expected to decline over the forecast period. This will occur as a result of government efforts to make digestive remedies more affordable.
* Advertising is expected to become more prominent for digestive remedies during the forecast period, with marketing activities becoming intense. Companies will spend more on advertising OTC digestive remedies, aiming to create a strong brand image in order to increase sales.[http://www.euromonitor.com/]

File:Forecasted figures for CAGR 0813.jpg

2010-04-16T12:02:28Z

Anand.shukla:

Digestive Remedies Market in India and China

2010-04-16T12:01:58Z

Anand.shukla: /* Forecasted Sales of Digestive Remedies */

=Market Overview=
==India==
* Digestive remedies in India saw current value growth of 7% in 2008, to reach Rs 8.5 billion
* Factors such as irregular eating habits, unhygienic food and stressful lifestyles have driven growth
* Digestive enzymes displayed the fastest growth, of 13% in current value terms, to reach Rs 1.7 billion
* GlaxoSmithKline Consumer Healthcare Ltd launched Eno Digesure in the first quarter of 2008
* Dabur India Ltd leads sales of digestive remedies, with a 26% value share, thanks largely to its Hajmola brand
* Sales of digestive remedies are predicted to grow by 17% in constant value terms over the forecast period[http://www.euromonitor.com/]

==China==

* Current value sales grow by 8% from 2007 to reach RMB3.8 billion in 2008
* Stressful and hectic lifestyles result in higher incidence of digestive problems
* Proton pump inhibitors see most dynamic current value growth of 14% in 2008
* Jilin Xiuzheng Pharmaceutical Co Ltd leads sales with 17% share of value sales in 2008
* Constant value CACR of 7% expected during forecast period[http://www.euromonitor.com/]

=Trends in Digestive remedies industry=

==India==

* Growth in digestive remedies in 2008 was led by urban consumers. Due to a growing economy and more hectic lifestyles, urban consumers increasingly skipped meals and ate out in sometimes unhygienic fast food outlets.
* Increasing stress led to constipation, diarrhoea and acidity, especially among young working adults. As a result, demand for digestive remedies was buoyant. In addition to this, lack of intake of nutrients in the form of fruits or dietary supplements further pushed growth.
* Heightened marketing activities by Dabur India Ltd for Hajmola drove digestive enzymes growth. Changes in positioning ensured that consumers perceived Hajmola as a must-have after every meal.
* For child-specific indigestion and heartburn remedies consumers started moving towards anti-spasmodic remedies.
* The value share of herbal/traditional products rose marginally in 2008, having declined in previous years. Dabur India Ltd continued to be the leading player in this area, with brands such as Hajmola and Pudin Hara.
* Due to the belief that standard/allopathic products have greater efficacy than their herbal/traditional counterparts, consumers generally prefer taking standard/allopathic products when it comes to treating severe bouts of acidity and other digestive ailments to get instant relief. However, consumers who take digestive remedies on a regular basis often prefer herbal/traditional products, due to their being less susceptible to side effects.
* Within indigestion remedies, the fastest growing type is digestive enzymes. Due to their positioning as a easy to take and without a medicinal taste, consumers are more comfortable using digestive enzymes on an everyday basis, unlike antacids which are positioned primarily as medicines. Hajmola’s tangy taste has endeared this brand to consumers from all age groups.
* Digestive ailments have risen, as consumers are rarely having a balanced diet, with regular intake of cereals, fruits or other dietary supplements. This trend has positively affected sales of antacids, digestive enzymes, laxatives and diarrhoeal remedies.
* UTC sales remained high in digestive remedies in 2008. Laxatives, diarrhoeal remedies, H2 blockers, motion sickness remedies and child specific products are where most UTC sales are seen. Brands such as Dulcolax, Cremaffin, Depandal and Stemetil enjoy long-standing brand loyalty, due to which they have virtually become household names and are freely sold without prescriptions.[http://www.euromonitor.com/]

==China==

* With rapid urbanisation and increasingly stressful lives, people developed increasingly irregular daily schedules. This trend was especially notable amongst the younger generation who increasingly live apart from their families.
* These consumers often have irregular meal times, which can cause digestive problems. For office workers, meanwhile, the time available for lunch is limited, with some being too busy to take lunch.
* Growth in digestive remedies in 2008 is slightly lower than in 2007. Many consumers became more health-conscious and adopted healthier diets, which led to a slowdown in growth for mature digestive remedies such as diarrhoeal remedies and laxatives. However, consumers’ growing confidence in selfmedicating with digestive remedies maintained good growth in 2008.
* Proton pump inhibitors saw the highest current value growth in 2008 over the previous year. These products are used for the prevention and treatment of acid-digestion conditions, such as ulcers and gastrooesophageal reflux disease (GERD).
* According to trade sources, GERD affects almost 7% of the population in China at some point. From a survey based on 7,000 GERD patients at the beginning of 2008, meanwhile, 70% of patients are aged 26-55-years-old. As proton pump inhibitors are more effective than traditional medicines and can relieve symptoms and heal the oesophageal lining for most who suffer from GERD, they became increasingly popular.
* Child-specific digestive remedies continued to see good growth in 2008. These products are influenced by very different factors than adult digestive remedies. Sales of adult digestive remedies are related mostly to consumers’ diets, stress levels and illness. Meanwhile, children’s digestive remedies saw sales boosted by parents purchasing decisions, with more parents opting for child-specific products for their children. These products offer fewer side-effects and are milder, with growing awareness of child-specific products resulting in them gaining popularity.
* Consumers also remain cautious about self-medication for children and prefer to take their children to a hospital for diagnosis in order to ensure their safety.
* Herbal/traditional products accounted for 22% of total value sales in digestive remedies in 2008, while standard products continue to dominate. Local consumers generally believe that herbal remedies are safe and good for long-term use, causing few side effects. This offers herbal/traditional products an advantage for some digestive diseases, which may need long-term care.
* For short-term digestive disorders and for rapid relief most prefer standard products as they believe standard products offer a more rapid effect.
* Most established herbal product in digestive remedies was Jiangzhong Pharmaceutical Co’s Jiangzhong in indigestion and heartburn remedies.
* IBS treatments are not available OTC. However, consumers can obtain these products via prescriptions or even under-the-counter (UTC) in some small pharmacies/drugstores. The UTC sales of IBS are however very small, as consumers prefer to seek medical advice for this long-term disorder from professionals.[http://www.euromonitor.com/]

==Competitive landscape==

==India==

* Dabur India Ltd led sales of digestive remedies in India in 2008. The company increased its value share to 26%, making it the fastest growing company in digestive remedies. Sales of Halmola were good while the sales of Pudin Hara were static due to an exceptionally short summer. The second placed manufacturer in 2008 was Abbott India Ltd, with its leading antacid brand, Digene.
* Sales of Cadila Healthcare Ltd, the marketer of best-selling laxative Dulcolax, have come under increasing pressure from the brand Duphalac, from Solvay Pharma Ltd. Consumers have shown a preference for lactulose-based brands, such as Duphalac, as they tend to be gentler on the stomach than bisacodyl-based brands, such as Dulcolax.
* Changing consumer preferences also led to sales of GlaxoSmithKline Pharmaceuticals Ltd and RPG Life Sciences Ltd in diarrhoeal remedies coming under pressure from Rx drugs, such as Cifran CT, from Ranbaxy Laboratories Ltd. Unlike brands such as Depandal, Lomotil and Lomofen, which simply provide relief from diarrhoea, drugs such as Cifran CT not only address diarrhoea in a patient, but also provide a more holistic benefit by working on the intestines and digestive system in general.
* Torrent Pharmaceuticals Ltd launched Fibotab in late 2007. The brand uses calcium polycarbophil as its API, and thus not only controls diarrhoea, but also treats constipation, thus making it a truly multipurpose drug. The brand has been positioned as better alternative to Isabgol.
* Novartis India ltd launched a new product Benefiber in 2008. A wheat dextrin-based laxative, the brand’s largest selling point is that it does not thicken and can be mixed with any beverage.
* Digestive remedies remained quite fragmented in 2008. Besides Dabur India Ltd and Abbott India Ltd, no other company managed to achieve a value share of more than 10%. Companies such as Pfizer Ltd, GlaxoSmithKline Pharmaceuticals Ltd and TTK Pharma Ltd lag behind with shares of around 4% to 5% each.
* Eno Digesure was launched by GlaxoSmithKline Consumer Healthcare Ltd in December 2007.[http://www.euromonitor.com/]

==China==

* Jilin Xiuzheng Pharmaceutical Co Ltd led digestive remedies with 17% value share in 2008. The company’s Si Da Shu brand is widely popular due to its clear product position and its differentiation of gastric diseases, offering variants for “stomach-ache”, “fullness” and “acid digestion”.
* Established local player Jiangzhong Pharmaceutical Co offers well-known herbal brand Jiangzhong Jian Wei Xiao Shi Pian in antiflatulents. In 2008, the company saw the biggest increase in value share in digestive remedies over the previous yea. Jian Wei Xiao Shi Pian is a generic traditional herbal remedy used to cure indigestion by easing stomach upsets and bloating.
* Domestic companies strived to gain share towards the end of the review period, benefiting from low prices and a wide distribution network.
* All of the leading domestic companies achieved GMP standards accreditation by the end of the review period, with product quality thus significantly improving.[http://www.euromonitor.com/]

=Digestive remedies category size and growth=

[[Image:Overall Digestive remedies market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese market is more then double of the Indian market and is expected to grow at a CAGR of 6.6%.
*While,Indian market will continue to grow at 3.1% on CAGR basis.
[[Image:Dihoral Remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese diarrhoeal remedies market is more then triple of the Indian market and is expected to grow at a CAGR of 5.6%.
*While,Indian market will continue to grow at 1.8% on CAGR basis.
[[Image:Indigestion and Heart Burn Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese Indigestion and heartburn remedies market is expected to grow at a CAGR of 6.9%.
*While,Indian market will continue to grow at 3.8% on CAGR basis.
[[Image:Motion Sickness Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese motion sickness remedies market is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.
[[Image:Child specific digestive remedies.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese child specific digestive remedies is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.

==Forecasted Sales of Digestive Remedies==

[[Image:Forecasted figures for Digestive remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
 
[[Image:Forecasted figures for CAGR 0813.jpg|center|thumb|500px|Source:Euromonitor]]

=Top digestive remedies companies and brands=
==India==
[[Image:india digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:india digestive brands1.jpg|center|thumb|500px|Source:Euromonitor]]

==China==
[[Image:china digestive brands.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:china digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
=Herbal vs Standard digestive remedies=
===India===
[[Image:india herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]
===China===
[[Image:china herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]

=Prevalence of Digestive Diseases in India and China=
===India===
[[Image:Divespive prevalence india.jpg|center|thumb|500px|Source:Cureresearch.com]]

===China===
[[Image:digestive prevalence china.jpg|center|thumb|500px|Source:Cureresearch.com]]

=Probiotics=

==Probiotics Market in India and China==

===Methodology===
[[Image:Probiotioc market estimation methodology1.jpg|thumb|500px|center|Methodology]]

===Results===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|'''Country'''
|align = "center"|'''Compared Geography'''
|align = "center"|'''Probiotic Market in US in Mn $'''
|align = "center"|'''US Population 2008 in Thousands'''
|align = "center"|'''Per Capita Probiotic Consumption (in $)'''
|align = "center"|'''PPP Adjustment Factor'''
|align = "center"|'''PPP Adjusted Consumption Per Capita in ($)'''
|align = "center"|'''Households with high Disposable Income (in thousands)'''
|align = "center"|'''Average number of people per household'''
|align = "center"|'''Potential Market for Probiotics (in Mn $)'''
|-
|align = "center" rowspan = "3"|'''India'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|2.73
|align = "center"|1.84
|align = "center" rowspan = "3"|4466.70
|align = "center" rowspan = "3"|5
|align = "center"|41.16
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.42
|align = "center"|3.40
|align = "center"|75.84
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|4.21
|align = "center"|3.54
|align = "center"|79.17
|-
|align = "center" rowspan = "3"|'''China'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|1.83
|align = "center"|2.75
|align = "center" rowspan = "3"|23163.9
|align = "center" rowspan = "3"|4
|align = "center"|254.77
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.01
|align = "center"|3.85
|align = "center"|356.71
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|2.82
|align = "center"|5.29
|align = "center"|490.50
|-
|}

*The households that are wealthy enough to consume such products on a regular basis are take as those having disposable income more then 15000$ per year.

=Product Dashboard=
[[Image:Digestive Product Dashboard.jpg|center|thumb|500px]]
* The product dashboard contains the names, effect and claims of various digestive remedies available in Indian and Chinese markets.[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=664 Click here] to view the dashboard.

=Prospects of digestive remedies industry=

===India===

* Increasingly busy lifestyles, irregular eating habits, lack of exercise and poor nutrition in meals will continue to be the main drivers of growth in sales of digestive remedies over the forecast period.
* Digestive problems such as constipation and acidity are likely to rise. In addition to this, lack of basic amenities, such as clean water and sanitary conditions in many rural and semi-urban parts of India, will give further impetus to growth, as these are the main causes of diarrhoea.
* The forecast period is expected to see growth a lot higher than that of the review period in constant value terms.
* Growth will be driven by increasing UTC consumption of proton pump inhibitors, antiflatulents, IBS treatments and H2 blockers. Consumers are expected to turn to advanced drugs like these in the hope of getting faster and long lasting relief from various digestive ailments.
* In the short term, growth in 2009 is expected to be marginally stronger than that in 2008, in spite of the economic downturn in India. Consumption of digestive remedies is expected to increase in line with a rise in population, which will naturally widen the consumer base.
* The review period saw many yoga centres being established in urban centres. Yoga is frequently touted as an effective way to control digestive ailments. If a “yoga revolution” does sweep across the country, growth in digestive remedies will again be negatively affected.
* Digestive enzymes are set to see the strongest growth over the forecast period, of 53% in constant value terms. Growth will be driven to a significant extent by Dabur India Ltd increasing penetration through aggressive marketing and promotional activities. Child-specific indigestion and heartburn remedies are expected to see the slowest growth between 2008 and 2013, of just 5% in constant value terms.
* Fibotab is expected to perform extremely well in the short term. The brand is expected to see success based on its multipurpose positioning as well as the fact that it does not need to be mixed with water, unlike Isabgol. On the other hand, Benefiber is not expected to do well, because of its high price and a lack of promotion by Novartis India Ltd.
* Companies might opt to position their products as meal supplements, instead of medicines, to take advantage of the growing trend to consume digestive remedies on a regular basis. Furthermore, companies will look to rural areas to drive further growth in sales, as urban areas are highly saturated when it comes to products such as antacids, diarrhoeal remedies and laxatives. Promotional activities are likely to include tying up with additional distributors, and conducting road shows and awareness programmes.[http://www.euromonitor.com/]

===China===

* Digestive remedies are expected to post moderate growth in most product areas during the forecast period. The continued acceleration of consumer lifestyles is expected to lead to an increasing number of people skipping meals or having irregular meal times. This will be the main factor maintaining demand for digestive remedies during the forecast period.
* Healthy eating and the widening use of vitamins and dietary supplements might pose a threat to digestive remedies during the forecast period. Sales of functional food products with high fibre content are expected to increase during the forecast period, while food containing prebiotics and/or probiotics such as yoghurt is also expected to see growing sales. These products can aid digestion and may reduce the incidence of digestive disorders.
* Moreover, consumers are increasingly opting for natural food instead of medicine under prevailing health trends. As a result, sales of diarrhoeal remedies are likely to be adversely affected.
* The decreasing demand for motion sickness remedies was led by the advancement of local transportation infrastructure. Moreover, the unit price of motion sickness remedies is low, at around RMB0.1 per tablet in 2008, with low prices also constraining value sales.
* Sales of motion sickness remedies are likely to remain sluggish during the forecast period, despite an increasing number of frequent travellers. This is because growth in the number of travellers is expected to mostly come from students and young adults. Many people in these groups do not bother taking motion sickness remedies and are often more accustomed to the discomfort caused by vehicle motion.
* Proton pump inhibitors is expected to see the fastest constant value growth in digestive remedies over the forecast period. Robust sales growth for the leading brand, AstraZeneca China Pharm Co Ltd’s Losec Mups, are likely to attract local manufacturers and other international brands, with new players thus set to enter this product area.
* As in other product areas of OTC healthcare, the unit price of digestive remedies is expected to decline over the forecast period. This will occur as a result of government efforts to make digestive remedies more affordable.
* Advertising is expected to become more prominent for digestive remedies during the forecast period, with marketing activities becoming intense. Companies will spend more on advertising OTC digestive remedies, aiming to create a strong brand image in order to increase sales.[http://www.euromonitor.com/]

Digestive Remedies Market in India and China

2010-04-16T12:01:16Z

Anand.shukla: /* Forecasted Sales of Digestive Remedies */

=Market Overview=
==India==
* Digestive remedies in India saw current value growth of 7% in 2008, to reach Rs 8.5 billion
* Factors such as irregular eating habits, unhygienic food and stressful lifestyles have driven growth
* Digestive enzymes displayed the fastest growth, of 13% in current value terms, to reach Rs 1.7 billion
* GlaxoSmithKline Consumer Healthcare Ltd launched Eno Digesure in the first quarter of 2008
* Dabur India Ltd leads sales of digestive remedies, with a 26% value share, thanks largely to its Hajmola brand
* Sales of digestive remedies are predicted to grow by 17% in constant value terms over the forecast period[http://www.euromonitor.com/]

==China==

* Current value sales grow by 8% from 2007 to reach RMB3.8 billion in 2008
* Stressful and hectic lifestyles result in higher incidence of digestive problems
* Proton pump inhibitors see most dynamic current value growth of 14% in 2008
* Jilin Xiuzheng Pharmaceutical Co Ltd leads sales with 17% share of value sales in 2008
* Constant value CACR of 7% expected during forecast period[http://www.euromonitor.com/]

=Trends in Digestive remedies industry=

==India==

* Growth in digestive remedies in 2008 was led by urban consumers. Due to a growing economy and more hectic lifestyles, urban consumers increasingly skipped meals and ate out in sometimes unhygienic fast food outlets.
* Increasing stress led to constipation, diarrhoea and acidity, especially among young working adults. As a result, demand for digestive remedies was buoyant. In addition to this, lack of intake of nutrients in the form of fruits or dietary supplements further pushed growth.
* Heightened marketing activities by Dabur India Ltd for Hajmola drove digestive enzymes growth. Changes in positioning ensured that consumers perceived Hajmola as a must-have after every meal.
* For child-specific indigestion and heartburn remedies consumers started moving towards anti-spasmodic remedies.
* The value share of herbal/traditional products rose marginally in 2008, having declined in previous years. Dabur India Ltd continued to be the leading player in this area, with brands such as Hajmola and Pudin Hara.
* Due to the belief that standard/allopathic products have greater efficacy than their herbal/traditional counterparts, consumers generally prefer taking standard/allopathic products when it comes to treating severe bouts of acidity and other digestive ailments to get instant relief. However, consumers who take digestive remedies on a regular basis often prefer herbal/traditional products, due to their being less susceptible to side effects.
* Within indigestion remedies, the fastest growing type is digestive enzymes. Due to their positioning as a easy to take and without a medicinal taste, consumers are more comfortable using digestive enzymes on an everyday basis, unlike antacids which are positioned primarily as medicines. Hajmola’s tangy taste has endeared this brand to consumers from all age groups.
* Digestive ailments have risen, as consumers are rarely having a balanced diet, with regular intake of cereals, fruits or other dietary supplements. This trend has positively affected sales of antacids, digestive enzymes, laxatives and diarrhoeal remedies.
* UTC sales remained high in digestive remedies in 2008. Laxatives, diarrhoeal remedies, H2 blockers, motion sickness remedies and child specific products are where most UTC sales are seen. Brands such as Dulcolax, Cremaffin, Depandal and Stemetil enjoy long-standing brand loyalty, due to which they have virtually become household names and are freely sold without prescriptions.[http://www.euromonitor.com/]

==China==

* With rapid urbanisation and increasingly stressful lives, people developed increasingly irregular daily schedules. This trend was especially notable amongst the younger generation who increasingly live apart from their families.
* These consumers often have irregular meal times, which can cause digestive problems. For office workers, meanwhile, the time available for lunch is limited, with some being too busy to take lunch.
* Growth in digestive remedies in 2008 is slightly lower than in 2007. Many consumers became more health-conscious and adopted healthier diets, which led to a slowdown in growth for mature digestive remedies such as diarrhoeal remedies and laxatives. However, consumers’ growing confidence in selfmedicating with digestive remedies maintained good growth in 2008.
* Proton pump inhibitors saw the highest current value growth in 2008 over the previous year. These products are used for the prevention and treatment of acid-digestion conditions, such as ulcers and gastrooesophageal reflux disease (GERD).
* According to trade sources, GERD affects almost 7% of the population in China at some point. From a survey based on 7,000 GERD patients at the beginning of 2008, meanwhile, 70% of patients are aged 26-55-years-old. As proton pump inhibitors are more effective than traditional medicines and can relieve symptoms and heal the oesophageal lining for most who suffer from GERD, they became increasingly popular.
* Child-specific digestive remedies continued to see good growth in 2008. These products are influenced by very different factors than adult digestive remedies. Sales of adult digestive remedies are related mostly to consumers’ diets, stress levels and illness. Meanwhile, children’s digestive remedies saw sales boosted by parents purchasing decisions, with more parents opting for child-specific products for their children. These products offer fewer side-effects and are milder, with growing awareness of child-specific products resulting in them gaining popularity.
* Consumers also remain cautious about self-medication for children and prefer to take their children to a hospital for diagnosis in order to ensure their safety.
* Herbal/traditional products accounted for 22% of total value sales in digestive remedies in 2008, while standard products continue to dominate. Local consumers generally believe that herbal remedies are safe and good for long-term use, causing few side effects. This offers herbal/traditional products an advantage for some digestive diseases, which may need long-term care.
* For short-term digestive disorders and for rapid relief most prefer standard products as they believe standard products offer a more rapid effect.
* Most established herbal product in digestive remedies was Jiangzhong Pharmaceutical Co’s Jiangzhong in indigestion and heartburn remedies.
* IBS treatments are not available OTC. However, consumers can obtain these products via prescriptions or even under-the-counter (UTC) in some small pharmacies/drugstores. The UTC sales of IBS are however very small, as consumers prefer to seek medical advice for this long-term disorder from professionals.[http://www.euromonitor.com/]

==Competitive landscape==

==India==

* Dabur India Ltd led sales of digestive remedies in India in 2008. The company increased its value share to 26%, making it the fastest growing company in digestive remedies. Sales of Halmola were good while the sales of Pudin Hara were static due to an exceptionally short summer. The second placed manufacturer in 2008 was Abbott India Ltd, with its leading antacid brand, Digene.
* Sales of Cadila Healthcare Ltd, the marketer of best-selling laxative Dulcolax, have come under increasing pressure from the brand Duphalac, from Solvay Pharma Ltd. Consumers have shown a preference for lactulose-based brands, such as Duphalac, as they tend to be gentler on the stomach than bisacodyl-based brands, such as Dulcolax.
* Changing consumer preferences also led to sales of GlaxoSmithKline Pharmaceuticals Ltd and RPG Life Sciences Ltd in diarrhoeal remedies coming under pressure from Rx drugs, such as Cifran CT, from Ranbaxy Laboratories Ltd. Unlike brands such as Depandal, Lomotil and Lomofen, which simply provide relief from diarrhoea, drugs such as Cifran CT not only address diarrhoea in a patient, but also provide a more holistic benefit by working on the intestines and digestive system in general.
* Torrent Pharmaceuticals Ltd launched Fibotab in late 2007. The brand uses calcium polycarbophil as its API, and thus not only controls diarrhoea, but also treats constipation, thus making it a truly multipurpose drug. The brand has been positioned as better alternative to Isabgol.
* Novartis India ltd launched a new product Benefiber in 2008. A wheat dextrin-based laxative, the brand’s largest selling point is that it does not thicken and can be mixed with any beverage.
* Digestive remedies remained quite fragmented in 2008. Besides Dabur India Ltd and Abbott India Ltd, no other company managed to achieve a value share of more than 10%. Companies such as Pfizer Ltd, GlaxoSmithKline Pharmaceuticals Ltd and TTK Pharma Ltd lag behind with shares of around 4% to 5% each.
* Eno Digesure was launched by GlaxoSmithKline Consumer Healthcare Ltd in December 2007.[http://www.euromonitor.com/]

==China==

* Jilin Xiuzheng Pharmaceutical Co Ltd led digestive remedies with 17% value share in 2008. The company’s Si Da Shu brand is widely popular due to its clear product position and its differentiation of gastric diseases, offering variants for “stomach-ache”, “fullness” and “acid digestion”.
* Established local player Jiangzhong Pharmaceutical Co offers well-known herbal brand Jiangzhong Jian Wei Xiao Shi Pian in antiflatulents. In 2008, the company saw the biggest increase in value share in digestive remedies over the previous yea. Jian Wei Xiao Shi Pian is a generic traditional herbal remedy used to cure indigestion by easing stomach upsets and bloating.
* Domestic companies strived to gain share towards the end of the review period, benefiting from low prices and a wide distribution network.
* All of the leading domestic companies achieved GMP standards accreditation by the end of the review period, with product quality thus significantly improving.[http://www.euromonitor.com/]

=Digestive remedies category size and growth=

[[Image:Overall Digestive remedies market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese market is more then double of the Indian market and is expected to grow at a CAGR of 6.6%.
*While,Indian market will continue to grow at 3.1% on CAGR basis.
[[Image:Dihoral Remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese diarrhoeal remedies market is more then triple of the Indian market and is expected to grow at a CAGR of 5.6%.
*While,Indian market will continue to grow at 1.8% on CAGR basis.
[[Image:Indigestion and Heart Burn Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese Indigestion and heartburn remedies market is expected to grow at a CAGR of 6.9%.
*While,Indian market will continue to grow at 3.8% on CAGR basis.
[[Image:Motion Sickness Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese motion sickness remedies market is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.
[[Image:Child specific digestive remedies.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese child specific digestive remedies is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.

==Forecasted Sales of Digestive Remedies==

[[Image:Forecasted figures for Digestive remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
 
[[Image:Forecasted figures for CAGR 0813|center|thumb|500px|Source:Euromonitor]]

=Top digestive remedies companies and brands=
==India==
[[Image:india digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:india digestive brands1.jpg|center|thumb|500px|Source:Euromonitor]]

==China==
[[Image:china digestive brands.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:china digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
=Herbal vs Standard digestive remedies=
===India===
[[Image:india herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]
===China===
[[Image:china herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]

=Prevalence of Digestive Diseases in India and China=
===India===
[[Image:Divespive prevalence india.jpg|center|thumb|500px|Source:Cureresearch.com]]

===China===
[[Image:digestive prevalence china.jpg|center|thumb|500px|Source:Cureresearch.com]]

=Probiotics=

==Probiotics Market in India and China==

===Methodology===
[[Image:Probiotioc market estimation methodology1.jpg|thumb|500px|center|Methodology]]

===Results===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|'''Country'''
|align = "center"|'''Compared Geography'''
|align = "center"|'''Probiotic Market in US in Mn $'''
|align = "center"|'''US Population 2008 in Thousands'''
|align = "center"|'''Per Capita Probiotic Consumption (in $)'''
|align = "center"|'''PPP Adjustment Factor'''
|align = "center"|'''PPP Adjusted Consumption Per Capita in ($)'''
|align = "center"|'''Households with high Disposable Income (in thousands)'''
|align = "center"|'''Average number of people per household'''
|align = "center"|'''Potential Market for Probiotics (in Mn $)'''
|-
|align = "center" rowspan = "3"|'''India'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|2.73
|align = "center"|1.84
|align = "center" rowspan = "3"|4466.70
|align = "center" rowspan = "3"|5
|align = "center"|41.16
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.42
|align = "center"|3.40
|align = "center"|75.84
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|4.21
|align = "center"|3.54
|align = "center"|79.17
|-
|align = "center" rowspan = "3"|'''China'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|1.83
|align = "center"|2.75
|align = "center" rowspan = "3"|23163.9
|align = "center" rowspan = "3"|4
|align = "center"|254.77
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.01
|align = "center"|3.85
|align = "center"|356.71
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|2.82
|align = "center"|5.29
|align = "center"|490.50
|-
|}

*The households that are wealthy enough to consume such products on a regular basis are take as those having disposable income more then 15000$ per year.

=Product Dashboard=
[[Image:Digestive Product Dashboard.jpg|center|thumb|500px]]
* The product dashboard contains the names, effect and claims of various digestive remedies available in Indian and Chinese markets.[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=664 Click here] to view the dashboard.

=Prospects of digestive remedies industry=

===India===

* Increasingly busy lifestyles, irregular eating habits, lack of exercise and poor nutrition in meals will continue to be the main drivers of growth in sales of digestive remedies over the forecast period.
* Digestive problems such as constipation and acidity are likely to rise. In addition to this, lack of basic amenities, such as clean water and sanitary conditions in many rural and semi-urban parts of India, will give further impetus to growth, as these are the main causes of diarrhoea.
* The forecast period is expected to see growth a lot higher than that of the review period in constant value terms.
* Growth will be driven by increasing UTC consumption of proton pump inhibitors, antiflatulents, IBS treatments and H2 blockers. Consumers are expected to turn to advanced drugs like these in the hope of getting faster and long lasting relief from various digestive ailments.
* In the short term, growth in 2009 is expected to be marginally stronger than that in 2008, in spite of the economic downturn in India. Consumption of digestive remedies is expected to increase in line with a rise in population, which will naturally widen the consumer base.
* The review period saw many yoga centres being established in urban centres. Yoga is frequently touted as an effective way to control digestive ailments. If a “yoga revolution” does sweep across the country, growth in digestive remedies will again be negatively affected.
* Digestive enzymes are set to see the strongest growth over the forecast period, of 53% in constant value terms. Growth will be driven to a significant extent by Dabur India Ltd increasing penetration through aggressive marketing and promotional activities. Child-specific indigestion and heartburn remedies are expected to see the slowest growth between 2008 and 2013, of just 5% in constant value terms.
* Fibotab is expected to perform extremely well in the short term. The brand is expected to see success based on its multipurpose positioning as well as the fact that it does not need to be mixed with water, unlike Isabgol. On the other hand, Benefiber is not expected to do well, because of its high price and a lack of promotion by Novartis India Ltd.
* Companies might opt to position their products as meal supplements, instead of medicines, to take advantage of the growing trend to consume digestive remedies on a regular basis. Furthermore, companies will look to rural areas to drive further growth in sales, as urban areas are highly saturated when it comes to products such as antacids, diarrhoeal remedies and laxatives. Promotional activities are likely to include tying up with additional distributors, and conducting road shows and awareness programmes.[http://www.euromonitor.com/]

===China===

* Digestive remedies are expected to post moderate growth in most product areas during the forecast period. The continued acceleration of consumer lifestyles is expected to lead to an increasing number of people skipping meals or having irregular meal times. This will be the main factor maintaining demand for digestive remedies during the forecast period.
* Healthy eating and the widening use of vitamins and dietary supplements might pose a threat to digestive remedies during the forecast period. Sales of functional food products with high fibre content are expected to increase during the forecast period, while food containing prebiotics and/or probiotics such as yoghurt is also expected to see growing sales. These products can aid digestion and may reduce the incidence of digestive disorders.
* Moreover, consumers are increasingly opting for natural food instead of medicine under prevailing health trends. As a result, sales of diarrhoeal remedies are likely to be adversely affected.
* The decreasing demand for motion sickness remedies was led by the advancement of local transportation infrastructure. Moreover, the unit price of motion sickness remedies is low, at around RMB0.1 per tablet in 2008, with low prices also constraining value sales.
* Sales of motion sickness remedies are likely to remain sluggish during the forecast period, despite an increasing number of frequent travellers. This is because growth in the number of travellers is expected to mostly come from students and young adults. Many people in these groups do not bother taking motion sickness remedies and are often more accustomed to the discomfort caused by vehicle motion.
* Proton pump inhibitors is expected to see the fastest constant value growth in digestive remedies over the forecast period. Robust sales growth for the leading brand, AstraZeneca China Pharm Co Ltd’s Losec Mups, are likely to attract local manufacturers and other international brands, with new players thus set to enter this product area.
* As in other product areas of OTC healthcare, the unit price of digestive remedies is expected to decline over the forecast period. This will occur as a result of government efforts to make digestive remedies more affordable.
* Advertising is expected to become more prominent for digestive remedies during the forecast period, with marketing activities becoming intense. Companies will spend more on advertising OTC digestive remedies, aiming to create a strong brand image in order to increase sales.[http://www.euromonitor.com/]

Digestive Remedies Market in India and China

2010-04-16T12:00:19Z

Anand.shukla: /* Digestive remedies category size and growth */

=Market Overview=
==India==
* Digestive remedies in India saw current value growth of 7% in 2008, to reach Rs 8.5 billion
* Factors such as irregular eating habits, unhygienic food and stressful lifestyles have driven growth
* Digestive enzymes displayed the fastest growth, of 13% in current value terms, to reach Rs 1.7 billion
* GlaxoSmithKline Consumer Healthcare Ltd launched Eno Digesure in the first quarter of 2008
* Dabur India Ltd leads sales of digestive remedies, with a 26% value share, thanks largely to its Hajmola brand
* Sales of digestive remedies are predicted to grow by 17% in constant value terms over the forecast period[http://www.euromonitor.com/]

==China==

* Current value sales grow by 8% from 2007 to reach RMB3.8 billion in 2008
* Stressful and hectic lifestyles result in higher incidence of digestive problems
* Proton pump inhibitors see most dynamic current value growth of 14% in 2008
* Jilin Xiuzheng Pharmaceutical Co Ltd leads sales with 17% share of value sales in 2008
* Constant value CACR of 7% expected during forecast period[http://www.euromonitor.com/]

=Trends in Digestive remedies industry=

==India==

* Growth in digestive remedies in 2008 was led by urban consumers. Due to a growing economy and more hectic lifestyles, urban consumers increasingly skipped meals and ate out in sometimes unhygienic fast food outlets.
* Increasing stress led to constipation, diarrhoea and acidity, especially among young working adults. As a result, demand for digestive remedies was buoyant. In addition to this, lack of intake of nutrients in the form of fruits or dietary supplements further pushed growth.
* Heightened marketing activities by Dabur India Ltd for Hajmola drove digestive enzymes growth. Changes in positioning ensured that consumers perceived Hajmola as a must-have after every meal.
* For child-specific indigestion and heartburn remedies consumers started moving towards anti-spasmodic remedies.
* The value share of herbal/traditional products rose marginally in 2008, having declined in previous years. Dabur India Ltd continued to be the leading player in this area, with brands such as Hajmola and Pudin Hara.
* Due to the belief that standard/allopathic products have greater efficacy than their herbal/traditional counterparts, consumers generally prefer taking standard/allopathic products when it comes to treating severe bouts of acidity and other digestive ailments to get instant relief. However, consumers who take digestive remedies on a regular basis often prefer herbal/traditional products, due to their being less susceptible to side effects.
* Within indigestion remedies, the fastest growing type is digestive enzymes. Due to their positioning as a easy to take and without a medicinal taste, consumers are more comfortable using digestive enzymes on an everyday basis, unlike antacids which are positioned primarily as medicines. Hajmola’s tangy taste has endeared this brand to consumers from all age groups.
* Digestive ailments have risen, as consumers are rarely having a balanced diet, with regular intake of cereals, fruits or other dietary supplements. This trend has positively affected sales of antacids, digestive enzymes, laxatives and diarrhoeal remedies.
* UTC sales remained high in digestive remedies in 2008. Laxatives, diarrhoeal remedies, H2 blockers, motion sickness remedies and child specific products are where most UTC sales are seen. Brands such as Dulcolax, Cremaffin, Depandal and Stemetil enjoy long-standing brand loyalty, due to which they have virtually become household names and are freely sold without prescriptions.[http://www.euromonitor.com/]

==China==

* With rapid urbanisation and increasingly stressful lives, people developed increasingly irregular daily schedules. This trend was especially notable amongst the younger generation who increasingly live apart from their families.
* These consumers often have irregular meal times, which can cause digestive problems. For office workers, meanwhile, the time available for lunch is limited, with some being too busy to take lunch.
* Growth in digestive remedies in 2008 is slightly lower than in 2007. Many consumers became more health-conscious and adopted healthier diets, which led to a slowdown in growth for mature digestive remedies such as diarrhoeal remedies and laxatives. However, consumers’ growing confidence in selfmedicating with digestive remedies maintained good growth in 2008.
* Proton pump inhibitors saw the highest current value growth in 2008 over the previous year. These products are used for the prevention and treatment of acid-digestion conditions, such as ulcers and gastrooesophageal reflux disease (GERD).
* According to trade sources, GERD affects almost 7% of the population in China at some point. From a survey based on 7,000 GERD patients at the beginning of 2008, meanwhile, 70% of patients are aged 26-55-years-old. As proton pump inhibitors are more effective than traditional medicines and can relieve symptoms and heal the oesophageal lining for most who suffer from GERD, they became increasingly popular.
* Child-specific digestive remedies continued to see good growth in 2008. These products are influenced by very different factors than adult digestive remedies. Sales of adult digestive remedies are related mostly to consumers’ diets, stress levels and illness. Meanwhile, children’s digestive remedies saw sales boosted by parents purchasing decisions, with more parents opting for child-specific products for their children. These products offer fewer side-effects and are milder, with growing awareness of child-specific products resulting in them gaining popularity.
* Consumers also remain cautious about self-medication for children and prefer to take their children to a hospital for diagnosis in order to ensure their safety.
* Herbal/traditional products accounted for 22% of total value sales in digestive remedies in 2008, while standard products continue to dominate. Local consumers generally believe that herbal remedies are safe and good for long-term use, causing few side effects. This offers herbal/traditional products an advantage for some digestive diseases, which may need long-term care.
* For short-term digestive disorders and for rapid relief most prefer standard products as they believe standard products offer a more rapid effect.
* Most established herbal product in digestive remedies was Jiangzhong Pharmaceutical Co’s Jiangzhong in indigestion and heartburn remedies.
* IBS treatments are not available OTC. However, consumers can obtain these products via prescriptions or even under-the-counter (UTC) in some small pharmacies/drugstores. The UTC sales of IBS are however very small, as consumers prefer to seek medical advice for this long-term disorder from professionals.[http://www.euromonitor.com/]

==Competitive landscape==

==India==

* Dabur India Ltd led sales of digestive remedies in India in 2008. The company increased its value share to 26%, making it the fastest growing company in digestive remedies. Sales of Halmola were good while the sales of Pudin Hara were static due to an exceptionally short summer. The second placed manufacturer in 2008 was Abbott India Ltd, with its leading antacid brand, Digene.
* Sales of Cadila Healthcare Ltd, the marketer of best-selling laxative Dulcolax, have come under increasing pressure from the brand Duphalac, from Solvay Pharma Ltd. Consumers have shown a preference for lactulose-based brands, such as Duphalac, as they tend to be gentler on the stomach than bisacodyl-based brands, such as Dulcolax.
* Changing consumer preferences also led to sales of GlaxoSmithKline Pharmaceuticals Ltd and RPG Life Sciences Ltd in diarrhoeal remedies coming under pressure from Rx drugs, such as Cifran CT, from Ranbaxy Laboratories Ltd. Unlike brands such as Depandal, Lomotil and Lomofen, which simply provide relief from diarrhoea, drugs such as Cifran CT not only address diarrhoea in a patient, but also provide a more holistic benefit by working on the intestines and digestive system in general.
* Torrent Pharmaceuticals Ltd launched Fibotab in late 2007. The brand uses calcium polycarbophil as its API, and thus not only controls diarrhoea, but also treats constipation, thus making it a truly multipurpose drug. The brand has been positioned as better alternative to Isabgol.
* Novartis India ltd launched a new product Benefiber in 2008. A wheat dextrin-based laxative, the brand’s largest selling point is that it does not thicken and can be mixed with any beverage.
* Digestive remedies remained quite fragmented in 2008. Besides Dabur India Ltd and Abbott India Ltd, no other company managed to achieve a value share of more than 10%. Companies such as Pfizer Ltd, GlaxoSmithKline Pharmaceuticals Ltd and TTK Pharma Ltd lag behind with shares of around 4% to 5% each.
* Eno Digesure was launched by GlaxoSmithKline Consumer Healthcare Ltd in December 2007.[http://www.euromonitor.com/]

==China==

* Jilin Xiuzheng Pharmaceutical Co Ltd led digestive remedies with 17% value share in 2008. The company’s Si Da Shu brand is widely popular due to its clear product position and its differentiation of gastric diseases, offering variants for “stomach-ache”, “fullness” and “acid digestion”.
* Established local player Jiangzhong Pharmaceutical Co offers well-known herbal brand Jiangzhong Jian Wei Xiao Shi Pian in antiflatulents. In 2008, the company saw the biggest increase in value share in digestive remedies over the previous yea. Jian Wei Xiao Shi Pian is a generic traditional herbal remedy used to cure indigestion by easing stomach upsets and bloating.
* Domestic companies strived to gain share towards the end of the review period, benefiting from low prices and a wide distribution network.
* All of the leading domestic companies achieved GMP standards accreditation by the end of the review period, with product quality thus significantly improving.[http://www.euromonitor.com/]

=Digestive remedies category size and growth=

[[Image:Overall Digestive remedies market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese market is more then double of the Indian market and is expected to grow at a CAGR of 6.6%.
*While,Indian market will continue to grow at 3.1% on CAGR basis.
[[Image:Dihoral Remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese diarrhoeal remedies market is more then triple of the Indian market and is expected to grow at a CAGR of 5.6%.
*While,Indian market will continue to grow at 1.8% on CAGR basis.
[[Image:Indigestion and Heart Burn Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese Indigestion and heartburn remedies market is expected to grow at a CAGR of 6.9%.
*While,Indian market will continue to grow at 3.8% on CAGR basis.
[[Image:Motion Sickness Market.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese motion sickness remedies market is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.
[[Image:Child specific digestive remedies.jpg|center|thumb|500px|Source:Euromonitor]]
*The Chinese child specific digestive remedies is expected to grow at a CAGR of 2.4%.
*While,Indian market will continue to grow at 1.3% on CAGR basis.

==Forecasted Sales of Digestive Remedies==

[[Image:Forecasted figures for Digestive remedies Market.jpg|center|thumb|500px|Source:Euromonitor]]
 
[[Image:Forecasted figures for CAGR 08-13|center|thumb|500px|Source:Euromonitor]]

=Top digestive remedies companies and brands=
==India==
[[Image:india digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:india digestive brands1.jpg|center|thumb|500px|Source:Euromonitor]]

==China==
[[Image:china digestive brands.jpg|center|thumb|500px|Source:Euromonitor]]
[[Image:china digestive companies.jpg|center|thumb|500px|Source:Euromonitor]]
=Herbal vs Standard digestive remedies=
===India===
[[Image:india herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]
===China===
[[Image:china herbal standard.jpg|center|thumb|500px|Source:Euromonitor]]

=Prevalence of Digestive Diseases in India and China=
===India===
[[Image:Divespive prevalence india.jpg|center|thumb|500px|Source:Cureresearch.com]]

===China===
[[Image:digestive prevalence china.jpg|center|thumb|500px|Source:Cureresearch.com]]

=Probiotics=

==Probiotics Market in India and China==

===Methodology===
[[Image:Probiotioc market estimation methodology1.jpg|thumb|500px|center|Methodology]]

===Results===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|'''Country'''
|align = "center"|'''Compared Geography'''
|align = "center"|'''Probiotic Market in US in Mn $'''
|align = "center"|'''US Population 2008 in Thousands'''
|align = "center"|'''Per Capita Probiotic Consumption (in $)'''
|align = "center"|'''PPP Adjustment Factor'''
|align = "center"|'''PPP Adjusted Consumption Per Capita in ($)'''
|align = "center"|'''Households with high Disposable Income (in thousands)'''
|align = "center"|'''Average number of people per household'''
|align = "center"|'''Potential Market for Probiotics (in Mn $)'''
|-
|align = "center" rowspan = "3"|'''India'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|2.73
|align = "center"|1.84
|align = "center" rowspan = "3"|4466.70
|align = "center" rowspan = "3"|5
|align = "center"|41.16
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.42
|align = "center"|3.40
|align = "center"|75.84
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|4.21
|align = "center"|3.54
|align = "center"|79.17
|-
|align = "center" rowspan = "3"|'''China'''
|US
|align = "center"|1530
|align = "center"|304060
|align = "center"|5.03
|align = "center"|1.83
|align = "center"|2.75
|align = "center" rowspan = "3"|23163.9
|align = "center" rowspan = "3"|4
|align = "center"|254.77
|-
|Europe
|align = "center"|3550
|align = "center"|306008
|align = "center"|11.60
|align = "center"|3.01
|align = "center"|3.85
|align = "center"|356.71
|-
|United Kingdom & Ireland
|align = "center"|971.75
|align = "center"|65100
|align = "center"|14.93
|align = "center"|2.82
|align = "center"|5.29
|align = "center"|490.50
|-
|}

*The households that are wealthy enough to consume such products on a regular basis are take as those having disposable income more then 15000$ per year.

=Product Dashboard=
[[Image:Digestive Product Dashboard.jpg|center|thumb|500px]]
* The product dashboard contains the names, effect and claims of various digestive remedies available in Indian and Chinese markets.[http://client.dolcera.com/dashboard/dashboard.html?workfile_id=664 Click here] to view the dashboard.

=Prospects of digestive remedies industry=

===India===

* Increasingly busy lifestyles, irregular eating habits, lack of exercise and poor nutrition in meals will continue to be the main drivers of growth in sales of digestive remedies over the forecast period.
* Digestive problems such as constipation and acidity are likely to rise. In addition to this, lack of basic amenities, such as clean water and sanitary conditions in many rural and semi-urban parts of India, will give further impetus to growth, as these are the main causes of diarrhoea.
* The forecast period is expected to see growth a lot higher than that of the review period in constant value terms.
* Growth will be driven by increasing UTC consumption of proton pump inhibitors, antiflatulents, IBS treatments and H2 blockers. Consumers are expected to turn to advanced drugs like these in the hope of getting faster and long lasting relief from various digestive ailments.
* In the short term, growth in 2009 is expected to be marginally stronger than that in 2008, in spite of the economic downturn in India. Consumption of digestive remedies is expected to increase in line with a rise in population, which will naturally widen the consumer base.
* The review period saw many yoga centres being established in urban centres. Yoga is frequently touted as an effective way to control digestive ailments. If a “yoga revolution” does sweep across the country, growth in digestive remedies will again be negatively affected.
* Digestive enzymes are set to see the strongest growth over the forecast period, of 53% in constant value terms. Growth will be driven to a significant extent by Dabur India Ltd increasing penetration through aggressive marketing and promotional activities. Child-specific indigestion and heartburn remedies are expected to see the slowest growth between 2008 and 2013, of just 5% in constant value terms.
* Fibotab is expected to perform extremely well in the short term. The brand is expected to see success based on its multipurpose positioning as well as the fact that it does not need to be mixed with water, unlike Isabgol. On the other hand, Benefiber is not expected to do well, because of its high price and a lack of promotion by Novartis India Ltd.
* Companies might opt to position their products as meal supplements, instead of medicines, to take advantage of the growing trend to consume digestive remedies on a regular basis. Furthermore, companies will look to rural areas to drive further growth in sales, as urban areas are highly saturated when it comes to products such as antacids, diarrhoeal remedies and laxatives. Promotional activities are likely to include tying up with additional distributors, and conducting road shows and awareness programmes.[http://www.euromonitor.com/]

===China===

* Digestive remedies are expected to post moderate growth in most product areas during the forecast period. The continued acceleration of consumer lifestyles is expected to lead to an increasing number of people skipping meals or having irregular meal times. This will be the main factor maintaining demand for digestive remedies during the forecast period.
* Healthy eating and the widening use of vitamins and dietary supplements might pose a threat to digestive remedies during the forecast period. Sales of functional food products with high fibre content are expected to increase during the forecast period, while food containing prebiotics and/or probiotics such as yoghurt is also expected to see growing sales. These products can aid digestion and may reduce the incidence of digestive disorders.
* Moreover, consumers are increasingly opting for natural food instead of medicine under prevailing health trends. As a result, sales of diarrhoeal remedies are likely to be adversely affected.
* The decreasing demand for motion sickness remedies was led by the advancement of local transportation infrastructure. Moreover, the unit price of motion sickness remedies is low, at around RMB0.1 per tablet in 2008, with low prices also constraining value sales.
* Sales of motion sickness remedies are likely to remain sluggish during the forecast period, despite an increasing number of frequent travellers. This is because growth in the number of travellers is expected to mostly come from students and young adults. Many people in these groups do not bother taking motion sickness remedies and are often more accustomed to the discomfort caused by vehicle motion.
* Proton pump inhibitors is expected to see the fastest constant value growth in digestive remedies over the forecast period. Robust sales growth for the leading brand, AstraZeneca China Pharm Co Ltd’s Losec Mups, are likely to attract local manufacturers and other international brands, with new players thus set to enter this product area.
* As in other product areas of OTC healthcare, the unit price of digestive remedies is expected to decline over the forecast period. This will occur as a result of government efforts to make digestive remedies more affordable.
* Advertising is expected to become more prominent for digestive remedies during the forecast period, with marketing activities becoming intense. Companies will spend more on advertising OTC digestive remedies, aiming to create a strong brand image in order to increase sales.[http://www.euromonitor.com/]

File:Probiotioc market estimation methodology1.jpg

2010-04-14T13:02:34Z

Anand.shukla:

Digestive Remedies Market in India and China

2010-04-14T13:02:13Z

2010-03-08T06:12:37Z

Main Page

2010-03-08T05:50:07Z

Anand.shukla: /* Business & Information Research Services */

__NOTOC__
===[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]===
===[[#Business & Information Research Services|Business and Information Research Services]]===
===[[#Dolcera Technology Platforms|Dolcera Technology Platform]]===

== Intellectual Property (IP) Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey;width:50%" valign = "top" |
===Life Sciences and Chemistry===
! style="background:lightgrey;width:50%" valign = "top" |
===Technology===
|-
| valign = "top" |
=== Landscape reports ===
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])
* [[Inflammation and cardiovascular drugs]]
* [[RNA Interference]]
* [[RNAi Database sample wiki]]
* [[Choline Bitartarate]]
* [[Non-wovens]]
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])
* [[Ureteral Stent]]
* [[Smart miniature drug delivery systems]]
* [[Silicone Hydrogel contact lens]]
* [[Biofuels database sample wiki]]
* [[SC Johnson]]
* [[Pinene: An off flavor in mango juice]]
| valign = "top" |

=== Landscape Reports ===
* [[Hybrid Electric Vehicle Battery System]]
* [[Supply Chain RFID Applications]]
* [[Insurance sector]]
* [[CDMA Basics]]
* [[Quality of Service on CDMA platforms]]
* [[OLED - Organic Light Emitting Diode]]
* [[Carbon Nanotubes (CNT)]]
* [[Metallic and Ceramic construction materials]]
* [[Transactional memory]]
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]
* [[Golf Club Head Landscape]]
* [[Interferon For Treatment of Melanoma]]
|-
| valign = "top" |

===STN Search Reports===
* [[Markush Search Report]]

=== Dashboard ===
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live]
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]])
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]
| valign = "top" |

=== Dashboard ===
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]
** [[Automotive Dashboard Screenshots|Screenshots only]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live]
** [[WiMAX Dashboard Screenshots|Screenshots only]]
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]

=== IP Valuation ===

[[Holographic Image Display]]
|-
| valign = "top" |

=== Prior Art / Invalidation / FTO Search ===
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]
* [[Markush Structure Search Sample]]
==== Study: In re Bilski Impact ====
* [[In re Bilski Impact assessed from US PAIR Information]]
| valign = "top" |

=== Prior Art / Invalidation / FTO Search ===
* [[Prior Art Search Process]]
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Map Sample]
|-
|}

===Clinical Trial Database===
*[[Clinical Trial Database]]

== Business & Information Research Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey" valign=top width=50%|
===Life Sciences and Chemistry===
! style="background:lightgrey" valign=top width=50%|
===Technology===
|-
| valign=top |
* [[Diabetes products and services]]
* [[Drug Metabolism]]
* [[Toxicology]]
* [[Osteoporosis]]
* [[Oral Diabetes Drugs]]
* [[Ureteral Stent]]
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]
* [[OTC products for acne treatment]]
* [[Botox - from Medical Procedure to Household Word]]
* [[Digestive Remedies Market in India and China]]
| valign=top |
* [[4G wireless technology developments]]
* [[HDTV in the US]]
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]
* [[Web video]]
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])
* [[Virtualization]]
* [[Cloud Computing]]
* [[Estimation of liquid carrying vehicles in USA]]
* [[A market study on Hybrid vehicles and the concept of V2G]]
|-
! style="background:lightgrey" valign=top colspan=2 |

===Finance===
|-
| valign=top colspan=2 |
* [[Innovative personal finance products]]
* [[Life Insurance Industry in US]]
|}

== Dolcera Technology Platforms ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
| align = "top" |
==== IP and Products dashboard ====
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard]
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]

==== Patent-pathway mapping ====
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]
==== Sequence dashboard ====
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]

==== Design analysis ====
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]

==== Innovation explorer ====
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]
==== KPort ====
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]

|-
|}

=== Dolcera Offerings summary ===
* [[Dolcera Offerings|Dolcera offerings summary]]

=== [[Technology Support]] ===

==Like any of these sample reports?==
 '''These are sample reports with brief analysis''' 
'''Dolcera can provide a comprehensive report customized to your needs'''
{|border="2" cellspacing="0" cellpadding="4" align="center" "
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com Buy the customized report from Dolcera]'''
|-
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
|-
|}
 

----
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"
|-
! style="background:lightgrey" | Contact Dolcera
|-
! style="background:lightgrey" | Samir Raiyani
|-
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]
|-
| '''Phone''': +1-650-269-7952, +91-40-2355-3493
|}

Interferon For Treatment of Melanoma

2009-11-17T11:16:14Z

Anand.shukla: /* Search in Micropatent MPI-INPADOC */

==Objective==

'''Primary objective of the study was to prepare a technology landscape on usage of interferon for the treatment of melanoma.'''

To achieve our objective we performed following steps:

*Create a multi level taxonomy to categorize the patents using interferon for melanoma treatment

*Mark out relevant IPC, ECLA, US classes and Japanese F-term available for technology in question.

*Identify and club relevant keywords with classes to extract relevant patents.

*Check for patents in US, EP, PCT, JP, Great Britain, and German patent records

*Perform MPI-INPADOC search which cover bibliographic data for 71 countries and legal status for 42 countries

*Analyze the patents and prepare a dashboard covering relevant patents for client usage.

==Overview==

===Interferon===

[[Image:interferon.jpg|250px|right|thumb|'''Interferon''' [http://upload.wikimedia.org/wikipedia/commons/5/52/1HIG_Interferon-Gamma01.png Source]]]

Interferons (IFNs) are natural cell-signaling proteins produced by the cells of the immune system of most vertebrates in response to challenges such as viruses, parasites and tumor cells. They belong to the large class of glycoproteins known as cytokines and are produced by a wide variety of cells in response to the presence of double-stranded RNA, a key indicator of viral infection. [http://en.wikipedia.org/wiki/Melanoma Source]

Interferons assist the immune response by inhibiting viral replication within host cells, activating natural killer cells and macrophages, increasing antigen presentation to T lymphocytes, and increasing the resistance of host cells to viral infection. There are 3 known classes of interferons; type I, type II and type III. All classes are very important in fighting viral infections. Recent studies have shown that Interferon can also help stop the growth and spread of cancer cells. [http://en.wikipedia.org/wiki/Interferon Source]

===Melanoma===

Melanoma is the most serious type of skin cancer. It begins in skin cells called melanocytes. Melanocytes are the cells that make melanin, which gives skin its color. Melanin also protects the deeper layers of the skin from the sun's harmful ultraviolet (UV) rays.When people spend time in the sunlight, the melanocytes make more melanin and cause the skin to tan. This also happens when skin is exposed to other forms of ultraviolet light (such as in a tanning booth). If the skin receives too much ultraviolet light, the melanocytes may begin to grow abnormally and become cancerous. This condition is called melanoma.People with melanoma who have one or more positive lymph nodes are at a high risk to have their melanoma recur. It is believed that 70 to 80% of these individuals will have their melanoma come back within the next three to five years. [http://www.melanoma.com/whatis.html Source]

===Interferon for treatment of melanoma===

Over the past several decades, the incidence of melanoma has increased at a faster rate than that of any other solid tumor. In the 1930s, the lifetime risk for a person living in the U.S. to develop melanoma was 1 in 1,500. Currently, that risk is 1 in 74, and for 2003 it was estimated that 51,400 cases of invasive melanoma would be diagnosed. While efforts to improve early diagnosis through education have resulted in the increased detection of early-stage melanoma, many patients still present with high-risk primary melanomas.

A beacon of hope in the treatment of melanoma has long been the observation that melanoma is susceptible to attack by the host’s immune system. This has resulted in the testing of a remarkably broad spectrum of immunotherapies, including the use of nonspecific immunostimulants, various approaches to vaccine therapies, and cytokine therapy. Many of these approaches failed to demonstrate a significant clinical impact, and the practitioner had been left with few options in treating high-risk melanoma patients with adjuvant therapy. One exception to this, however, has been the use of adjuvant interferon alpha (IFN-{alpha})

While the precise mechanism of action remains poorly understood, there are multiple antitumor effects of IFN-{alpha}. These include a direct antiproliferative effect, the enhancement of natural killer cell activity, and the upregulation of tumor antigens and/or HLA class I and class II antigens. Initial phase II clinical studies with IFN-{alpha} in metastatic melanoma showed response rates in the 10%–20% range [4, 5]. These response rates, while encouraging, were not significant enough to lead to its widespread use in the treatment of metastatic melanoma. [http://theoncologist.alphamedpress.org/cgi/content/full/8/5/451 Source]

===Taxonomy===

[[Image:taxonomy melanoma mod1.jpg|700px|center|thumb| '''Taxonomy''']]

==Intellectual property==

===Search strategy and concept===

Date of Search: 1836 to October 26, 2009
Database used: Micropatent - Include extensive full text and MPI-Inpadoc searches

===Search in Micropatent full text===

Micro patent full text search allow search in fulltext of US, EP, PCT, Great Britain, and German patent records as well as the front page of JP documents. US, EP, and DE are covered at first publication and when granted.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''Sr. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search reason'''
|align = "center" bgcolor = "#99CCFF"|'''Class Code (IPC,US,ECLA)'''
|align = "center" bgcolor = "#99CCFF"|'''Search query'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|Specific classes of interferon AND melanoma keywords
|align = "center"|A61K003821<nowiki>*</nowiki> OR C07K014555 OR C07K001456 OR C07K014565 OR C07K001457 OR C07K014715G OR 4240854 OR 4242811 OR 42400141 OR 514889 OR 530351 OR 930142
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|576
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|Broad classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K003819 OR C07K001452 OR 4240851 OR 4240855 OR 4240856 OR 4240857 OR A61P003500
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|756
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|'''Final query'''
|align = "center" colspan = "4"|'''1 OR 2'''
|align = "center"|1019 records '''571 unique records'''
|-
|}

===Search in Micropatent MPI-INPADOC===

Micrpatent MPI-INPADOC search bibliographic data for 71 countries and legal status for 42. Only those patents were analyzed which have English title and/or abstract.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''Sr. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search reason'''
|align = "center" bgcolor = "#99CCFF"|'''Class search'''
|align = "center" bgcolor = "#99CCFF"|'''Search query'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Specific IPC classes of interferon AND melanoma keywords
|align = "center"|A61K03821 OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|174
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Broad IPC classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K03819 OR C07K01452 OR A61P03500
|align = "center"|(IFN<nowiki>*</nowiki> OR <nowiki>*</nowiki>IFN OR interferon<nowiki>*</nowiki> OR <nowiki>*</nowiki>interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|484
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Specific ECLA classes of interferon AND melanoma keywords
|align = "center"|A61K03821<nowiki>*</nowiki> OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457 OR C07K014715G
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|102
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Broad ECLA classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K03819 OR C07K01452 OR A61P03500
|align = "center"|(IFN<nowiki>*</nowiki> OR <nowiki>*</nowiki>IFN OR interferon<nowiki>*</nowiki> OR <nowiki>*</nowiki>interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|9
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center" colspan = "4"|'''Final query'''
|align = "center"|'''1 OR 2 OR 3 OR 4'''
|align = "center"|587 hits '''232 unique records'''
|-
|}

===Class codes used in searches===

* '''Relevant IPC classes'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''IPC'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|align = "center" bgcolor = "#C0C0C0"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing peptides Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|A61P003500
|align = "center"|Therapeutic activity of chemical compounds or medicinal preparations -antineoplastic agents
|align = "center"|Broad
|-
|}

* '''Relevant ECLA classes'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''ECLA'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|align = "center" bgcolor = "#C0C0C0"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|A61K38/21A
|align = "center"|Medicinal preparations containing IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|A61K38/21B
|align = "center"|Medicinal preparations containing IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|A61K38/21C
|align = "center"|Medicinal preparations containing IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''9'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''10'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''11'''
|align = "center"|C07K014715G
|align = "center"|Receptors; Cell surface antigens; Cell surface determinants - for interferons -
|align = "center"|Specific
|-
|}

* '''Relevant US classes'''

{|border="2" cellspacing="0" cellpadding="4" width="50%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''US class'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|4240854
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - this subclass provides for patents which broadly claim interferon or a method of treatment of interferon where the classification of the interferon as alpha, beta or gamma interferon is impossible
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|4242811
|align = "center"| DRUG, BIO-AFFCTING AND BODY TREATING COMPOSITIONS - Virus (e.g., interferon-inducing virus, etc.)
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|42400141
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|514889
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - INTERFERON INDUCER
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|530351
|align = "center"| CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF - Lymphokines, e.g., interferons, interlukins, etc.
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|930142
|align = "center"|PEPTIDE OR PROTEIN SEQUENCE - Interferon
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|4240851
|align = "center"|LYMPHOKINE - Included in this and the indented subclasses interferon, interleukin and macrophage factors (monokines)
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|4240855
|align = "center"|Gamma or immune: This subclass is indented under subclass 85.4. Subject matter in which the interferon is gamma or immune interferon.
|-
|align = "center" bgcolor = "#C0C0C0"|'''9'''
|align = "center"|4240856
|align = "center"|Subject matter in which the interferon is beta or fibroblast interferon.
|-
|align = "center" bgcolor = "#C0C0C0"|'''10'''
|align = "center"|4240857
|align = "center"|Subject matter in which the interferon is alpha or leukocyte interferon.
|-
|}

===Search in Japanese database===

Database: IPDL (Industrial property digital library), Japan

Date of search: 1900/01/01 to 2009/10/26

'''Total patents: 846 (Relevancy ~10%)'''

* '''F-Terms and theme used in search'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''Japanese F-term search'''
|align = "center" bgcolor = "#99CCFF"|'''Definition'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center"|'''F- Term theme'''
|align = "center"|'''4H045'''
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereo
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|F-term
|align = "center"|DA15
|align = "center"|Peptide or protein characterised by function - Interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|F-term
|align = "center"|DA16
|align = "center"|Alpha-interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|F-term
|align = "center"|DA17
|align = "center"|Beta-interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|F-term
|align = "center"|DA18
|align = "center"|Gamma-interferons
|-
|}

==Sample patents==

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#C0C0C0"|'''S.No.'''
|align = "center" bgcolor = "#99CCFF"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#99CCFF"|'''Date of Publication'''
|align = "center" bgcolor = "#99CCFF"|'''Assignee / Applicant'''
|align = "center" bgcolor = "#99CCFF"|'''Inventor(s)'''
|align = "center" bgcolor = "#99CCFF"|'''Title'''
|align = "center" bgcolor = "#C0C0C0"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20051027&CC=US&NR=2005238621A1&KC=A1 US7482014B2]
|align = "center"|1/27/2009
|align = "center"|Schering Corporation
|align = "center"|Rybak, Mary Ellen and Rose, Esther Helen
|align = "center"|Melanoma therapy
|align = "center"|The invention relates to a method of treating a patient having Stage IIB or Stage III melanoma which has been surgically removed. A first dose of 6.0 micrograms/kg of pegylated interferon alpha-2b once a week for eight weeks, and then administering to the patient a second dose of 3.0 or less micrograms/kg of pegylated interferon alpha-2b once a week for the remainder of a five year treatment period.
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19991207&CC=US&NR=5997858A&KC=A US5997858A]
|align = "center"|12/7/1999
|align = "center"|Pharma Pacific Pty Ltd.
|align = "center"|Tovey, Michael Gerard and Kaido, Thomas James
|align = "center"|Stimulation of host defense mechanisms against tumors
|align = "center"|A method for treating multiple myeloma, hairy cell leukemia, malignant melanoma, brain tumors etc. by administering a therapeutically effective amount of an interferon (1500 IU to about 20×106 IU for a 70 kg man per day) via oromucosal contact.
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19881026&CC=EP&NR=0288055A1&KC=A1 EP288055A1]
|align = "center"|10/26/1988
|align = "center"|MERRELL DOW PHARMACEUTICALS INC.
|align = "center"|Sunkara, Sai P.
|align = "center"|Use of ODC inhibitors, dacarbazine, and interferon, in the treatment of malignant melanoma
|align = "center"|A combinational therapy containing an ornithine decarboxylase inhibitor, Interferon and Dacarbazine for simultaneous, separate or sequential use in treating rapidly-proliferating cell-growth disease such as melanoma.
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19871014&CC=EP&NR=0241242A1&KC=A1 EP241242A1]
|align = "center"|10/14/1987
|align = "center"|CETUS ONCOLOGY CORPORATION
|align = "center"|Rudolph, Alfred
|align = "center"|The use of interferon-beta and interleukin-2 for combination therapy and compositions therefor
|align = "center"|A composition comprising of a mixture of lFN- beta and IL-2 for administration to human patients for therapeutic or prophylactic treatment of cancer such as colon cancer, melanoma, renal cell cancer, lung cancer.
|-
|}

Interferon For Treatment of Melanoma

2009-11-17T11:15:56Z

Anand.shukla: /* Search in Micropatent full text */

==Objective==

'''Primary objective of the study was to prepare a technology landscape on usage of interferon for the treatment of melanoma.'''

To achieve our objective we performed following steps:

*Create a multi level taxonomy to categorize the patents using interferon for melanoma treatment

*Mark out relevant IPC, ECLA, US classes and Japanese F-term available for technology in question.

*Identify and club relevant keywords with classes to extract relevant patents.

*Check for patents in US, EP, PCT, JP, Great Britain, and German patent records

*Perform MPI-INPADOC search which cover bibliographic data for 71 countries and legal status for 42 countries

*Analyze the patents and prepare a dashboard covering relevant patents for client usage.

==Overview==

===Interferon===

[[Image:interferon.jpg|250px|right|thumb|'''Interferon''' [http://upload.wikimedia.org/wikipedia/commons/5/52/1HIG_Interferon-Gamma01.png Source]]]

Interferons (IFNs) are natural cell-signaling proteins produced by the cells of the immune system of most vertebrates in response to challenges such as viruses, parasites and tumor cells. They belong to the large class of glycoproteins known as cytokines and are produced by a wide variety of cells in response to the presence of double-stranded RNA, a key indicator of viral infection. [http://en.wikipedia.org/wiki/Melanoma Source]

Interferons assist the immune response by inhibiting viral replication within host cells, activating natural killer cells and macrophages, increasing antigen presentation to T lymphocytes, and increasing the resistance of host cells to viral infection. There are 3 known classes of interferons; type I, type II and type III. All classes are very important in fighting viral infections. Recent studies have shown that Interferon can also help stop the growth and spread of cancer cells. [http://en.wikipedia.org/wiki/Interferon Source]

===Melanoma===

Melanoma is the most serious type of skin cancer. It begins in skin cells called melanocytes. Melanocytes are the cells that make melanin, which gives skin its color. Melanin also protects the deeper layers of the skin from the sun's harmful ultraviolet (UV) rays.When people spend time in the sunlight, the melanocytes make more melanin and cause the skin to tan. This also happens when skin is exposed to other forms of ultraviolet light (such as in a tanning booth). If the skin receives too much ultraviolet light, the melanocytes may begin to grow abnormally and become cancerous. This condition is called melanoma.People with melanoma who have one or more positive lymph nodes are at a high risk to have their melanoma recur. It is believed that 70 to 80% of these individuals will have their melanoma come back within the next three to five years. [http://www.melanoma.com/whatis.html Source]

===Interferon for treatment of melanoma===

Over the past several decades, the incidence of melanoma has increased at a faster rate than that of any other solid tumor. In the 1930s, the lifetime risk for a person living in the U.S. to develop melanoma was 1 in 1,500. Currently, that risk is 1 in 74, and for 2003 it was estimated that 51,400 cases of invasive melanoma would be diagnosed. While efforts to improve early diagnosis through education have resulted in the increased detection of early-stage melanoma, many patients still present with high-risk primary melanomas.

A beacon of hope in the treatment of melanoma has long been the observation that melanoma is susceptible to attack by the host’s immune system. This has resulted in the testing of a remarkably broad spectrum of immunotherapies, including the use of nonspecific immunostimulants, various approaches to vaccine therapies, and cytokine therapy. Many of these approaches failed to demonstrate a significant clinical impact, and the practitioner had been left with few options in treating high-risk melanoma patients with adjuvant therapy. One exception to this, however, has been the use of adjuvant interferon alpha (IFN-{alpha})

While the precise mechanism of action remains poorly understood, there are multiple antitumor effects of IFN-{alpha}. These include a direct antiproliferative effect, the enhancement of natural killer cell activity, and the upregulation of tumor antigens and/or HLA class I and class II antigens. Initial phase II clinical studies with IFN-{alpha} in metastatic melanoma showed response rates in the 10%–20% range [4, 5]. These response rates, while encouraging, were not significant enough to lead to its widespread use in the treatment of metastatic melanoma. [http://theoncologist.alphamedpress.org/cgi/content/full/8/5/451 Source]

===Taxonomy===

[[Image:taxonomy melanoma mod1.jpg|700px|center|thumb| '''Taxonomy''']]

==Intellectual property==

===Search strategy and concept===

Date of Search: 1836 to October 26, 2009
Database used: Micropatent - Include extensive full text and MPI-Inpadoc searches

===Search in Micropatent full text===

Micro patent full text search allow search in fulltext of US, EP, PCT, Great Britain, and German patent records as well as the front page of JP documents. US, EP, and DE are covered at first publication and when granted.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''Sr. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search reason'''
|align = "center" bgcolor = "#99CCFF"|'''Class Code (IPC,US,ECLA)'''
|align = "center" bgcolor = "#99CCFF"|'''Search query'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|Specific classes of interferon AND melanoma keywords
|align = "center"|A61K003821<nowiki>*</nowiki> OR C07K014555 OR C07K001456 OR C07K014565 OR C07K001457 OR C07K014715G OR 4240854 OR 4242811 OR 42400141 OR 514889 OR 530351 OR 930142
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|576
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|Broad classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K003819 OR C07K001452 OR 4240851 OR 4240855 OR 4240856 OR 4240857 OR A61P003500
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|756
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|'''Final query'''
|align = "center" colspan = "4"|'''1 OR 2'''
|align = "center"|1019 records '''571 unique records'''
|-
|}

===Search in Micropatent MPI-INPADOC===

Micrpatent MPI-INPADOC search bibliographic data for 71 countries and legal status for 42. Only those patents were analyzed which have English title and/or abstract.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''Sr. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search reason'''
|align = "center" bgcolor = "#99CCFF"|'''Class search'''
|align = "center" bgcolor = "#99CCFF"|'''Search quey'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Specific IPC classes of interferon AND melanoma keywords
|align = "center"|A61K03821 OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|174
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Broad IPC classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K03819 OR C07K01452 OR A61P03500
|align = "center"|(IFN<nowiki>*</nowiki> OR <nowiki>*</nowiki>IFN OR interferon<nowiki>*</nowiki> OR <nowiki>*</nowiki>interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|484
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Specific ECLA classes of interferon AND melanoma keywords
|align = "center"|A61K03821<nowiki>*</nowiki> OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457 OR C07K014715G
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|102
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Broad ECLA classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K03819 OR C07K01452 OR A61P03500
|align = "center"|(IFN<nowiki>*</nowiki> OR <nowiki>*</nowiki>IFN OR interferon<nowiki>*</nowiki> OR <nowiki>*</nowiki>interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|9
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center" colspan = "4"|'''Final query'''
|align = "center"|'''1 OR 2 OR 3 OR 4'''
|align = "center"|587 hits '''232 unique records'''
|-
|}

===Class codes used in searches===

* '''Relevant IPC classes'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''IPC'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|align = "center" bgcolor = "#C0C0C0"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing peptides Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|A61P003500
|align = "center"|Therapeutic activity of chemical compounds or medicinal preparations -antineoplastic agents
|align = "center"|Broad
|-
|}

* '''Relevant ECLA classes'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''ECLA'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|align = "center" bgcolor = "#C0C0C0"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|A61K38/21A
|align = "center"|Medicinal preparations containing IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|A61K38/21B
|align = "center"|Medicinal preparations containing IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|A61K38/21C
|align = "center"|Medicinal preparations containing IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''9'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''10'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''11'''
|align = "center"|C07K014715G
|align = "center"|Receptors; Cell surface antigens; Cell surface determinants - for interferons -
|align = "center"|Specific
|-
|}

* '''Relevant US classes'''

{|border="2" cellspacing="0" cellpadding="4" width="50%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''US class'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|4240854
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - this subclass provides for patents which broadly claim interferon or a method of treatment of interferon where the classification of the interferon as alpha, beta or gamma interferon is impossible
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|4242811
|align = "center"| DRUG, BIO-AFFCTING AND BODY TREATING COMPOSITIONS - Virus (e.g., interferon-inducing virus, etc.)
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|42400141
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|514889
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - INTERFERON INDUCER
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|530351
|align = "center"| CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF - Lymphokines, e.g., interferons, interlukins, etc.
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|930142
|align = "center"|PEPTIDE OR PROTEIN SEQUENCE - Interferon
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|4240851
|align = "center"|LYMPHOKINE - Included in this and the indented subclasses interferon, interleukin and macrophage factors (monokines)
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|4240855
|align = "center"|Gamma or immune: This subclass is indented under subclass 85.4. Subject matter in which the interferon is gamma or immune interferon.
|-
|align = "center" bgcolor = "#C0C0C0"|'''9'''
|align = "center"|4240856
|align = "center"|Subject matter in which the interferon is beta or fibroblast interferon.
|-
|align = "center" bgcolor = "#C0C0C0"|'''10'''
|align = "center"|4240857
|align = "center"|Subject matter in which the interferon is alpha or leukocyte interferon.
|-
|}

===Search in Japanese database===

Database: IPDL (Industrial property digital library), Japan

Date of search: 1900/01/01 to 2009/10/26

'''Total patents: 846 (Relevancy ~10%)'''

* '''F-Terms and theme used in search'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''Japanese F-term search'''
|align = "center" bgcolor = "#99CCFF"|'''Definition'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center"|'''F- Term theme'''
|align = "center"|'''4H045'''
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereo
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|F-term
|align = "center"|DA15
|align = "center"|Peptide or protein characterised by function - Interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|F-term
|align = "center"|DA16
|align = "center"|Alpha-interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|F-term
|align = "center"|DA17
|align = "center"|Beta-interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|F-term
|align = "center"|DA18
|align = "center"|Gamma-interferons
|-
|}

==Sample patents==

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#C0C0C0"|'''S.No.'''
|align = "center" bgcolor = "#99CCFF"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#99CCFF"|'''Date of Publication'''
|align = "center" bgcolor = "#99CCFF"|'''Assignee / Applicant'''
|align = "center" bgcolor = "#99CCFF"|'''Inventor(s)'''
|align = "center" bgcolor = "#99CCFF"|'''Title'''
|align = "center" bgcolor = "#C0C0C0"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20051027&CC=US&NR=2005238621A1&KC=A1 US7482014B2]
|align = "center"|1/27/2009
|align = "center"|Schering Corporation
|align = "center"|Rybak, Mary Ellen and Rose, Esther Helen
|align = "center"|Melanoma therapy
|align = "center"|The invention relates to a method of treating a patient having Stage IIB or Stage III melanoma which has been surgically removed. A first dose of 6.0 micrograms/kg of pegylated interferon alpha-2b once a week for eight weeks, and then administering to the patient a second dose of 3.0 or less micrograms/kg of pegylated interferon alpha-2b once a week for the remainder of a five year treatment period.
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19991207&CC=US&NR=5997858A&KC=A US5997858A]
|align = "center"|12/7/1999
|align = "center"|Pharma Pacific Pty Ltd.
|align = "center"|Tovey, Michael Gerard and Kaido, Thomas James
|align = "center"|Stimulation of host defense mechanisms against tumors
|align = "center"|A method for treating multiple myeloma, hairy cell leukemia, malignant melanoma, brain tumors etc. by administering a therapeutically effective amount of an interferon (1500 IU to about 20×106 IU for a 70 kg man per day) via oromucosal contact.
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19881026&CC=EP&NR=0288055A1&KC=A1 EP288055A1]
|align = "center"|10/26/1988
|align = "center"|MERRELL DOW PHARMACEUTICALS INC.
|align = "center"|Sunkara, Sai P.
|align = "center"|Use of ODC inhibitors, dacarbazine, and interferon, in the treatment of malignant melanoma
|align = "center"|A combinational therapy containing an ornithine decarboxylase inhibitor, Interferon and Dacarbazine for simultaneous, separate or sequential use in treating rapidly-proliferating cell-growth disease such as melanoma.
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19871014&CC=EP&NR=0241242A1&KC=A1 EP241242A1]
|align = "center"|10/14/1987
|align = "center"|CETUS ONCOLOGY CORPORATION
|align = "center"|Rudolph, Alfred
|align = "center"|The use of interferon-beta and interleukin-2 for combination therapy and compositions therefor
|align = "center"|A composition comprising of a mixture of lFN- beta and IL-2 for administration to human patients for therapeutic or prophylactic treatment of cancer such as colon cancer, melanoma, renal cell cancer, lung cancer.
|-
|}

File:DSlide 7.JPG.jpg

2009-11-17T11:14:24Z

Anand.shukla:

File:DSlide 2.JPG.jpg

2009-11-17T11:14:18Z

Anand.shukla:

Prior Art Search Process

2009-11-17T11:13:58Z

Anand.shukla:

Interferon For Treatment of Melanoma

2009-11-17T11:06:10Z

Anand.shukla:

==Objective==

'''Primary objective of the study was to prepare a technology landscape on usage of interferon for the treatment of melanoma.'''

To achieve our objective we performed following steps:

*Create a multi level taxonomy to categorize the patents using interferon for melanoma treatment

*Mark out relevant IPC, ECLA, US classes and Japanese F-term available for technology in question.

*Identify and club relevant keywords with classes to extract relevant patents.

*Check for patents in US, EP, PCT, JP, Great Britain, and German patent records

*Perform MPI-INPADOC search which cover bibliographic data for 71 countries and legal status for 42 countries

*Analyze the patents and prepare a dashboard covering relevant patents for client usage.

==Overview==

===Interferon===

[[Image:interferon.jpg|250px|right|thumb|'''Interferon''' [http://upload.wikimedia.org/wikipedia/commons/5/52/1HIG_Interferon-Gamma01.png Source]]]

Interferons (IFNs) are natural cell-signaling proteins produced by the cells of the immune system of most vertebrates in response to challenges such as viruses, parasites and tumor cells. They belong to the large class of glycoproteins known as cytokines and are produced by a wide variety of cells in response to the presence of double-stranded RNA, a key indicator of viral infection. [http://en.wikipedia.org/wiki/Melanoma Source]

Interferons assist the immune response by inhibiting viral replication within host cells, activating natural killer cells and macrophages, increasing antigen presentation to T lymphocytes, and increasing the resistance of host cells to viral infection. There are 3 known classes of interferons; type I, type II and type III. All classes are very important in fighting viral infections. Recent studies have shown that Interferon can also help stop the growth and spread of cancer cells. [http://en.wikipedia.org/wiki/Interferon Source]

===Melanoma===

Melanoma is the most serious type of skin cancer. It begins in skin cells called melanocytes. Melanocytes are the cells that make melanin, which gives skin its color. Melanin also protects the deeper layers of the skin from the sun's harmful ultraviolet (UV) rays.When people spend time in the sunlight, the melanocytes make more melanin and cause the skin to tan. This also happens when skin is exposed to other forms of ultraviolet light (such as in a tanning booth). If the skin receives too much ultraviolet light, the melanocytes may begin to grow abnormally and become cancerous. This condition is called melanoma.People with melanoma who have one or more positive lymph nodes are at a high risk to have their melanoma recur. It is believed that 70 to 80% of these individuals will have their melanoma come back within the next three to five years. [http://www.melanoma.com/whatis.html Source]

===Interferon for treatment of melanoma===

Over the past several decades, the incidence of melanoma has increased at a faster rate than that of any other solid tumor. In the 1930s, the lifetime risk for a person living in the U.S. to develop melanoma was 1 in 1,500. Currently, that risk is 1 in 74, and for 2003 it was estimated that 51,400 cases of invasive melanoma would be diagnosed. While efforts to improve early diagnosis through education have resulted in the increased detection of early-stage melanoma, many patients still present with high-risk primary melanomas.

A beacon of hope in the treatment of melanoma has long been the observation that melanoma is susceptible to attack by the host’s immune system. This has resulted in the testing of a remarkably broad spectrum of immunotherapies, including the use of nonspecific immunostimulants, various approaches to vaccine therapies, and cytokine therapy. Many of these approaches failed to demonstrate a significant clinical impact, and the practitioner had been left with few options in treating high-risk melanoma patients with adjuvant therapy. One exception to this, however, has been the use of adjuvant interferon alpha (IFN-{alpha})

While the precise mechanism of action remains poorly understood, there are multiple antitumor effects of IFN-{alpha}. These include a direct antiproliferative effect, the enhancement of natural killer cell activity, and the upregulation of tumor antigens and/or HLA class I and class II antigens. Initial phase II clinical studies with IFN-{alpha} in metastatic melanoma showed response rates in the 10%–20% range [4, 5]. These response rates, while encouraging, were not significant enough to lead to its widespread use in the treatment of metastatic melanoma. [http://theoncologist.alphamedpress.org/cgi/content/full/8/5/451 Source]

===Taxonomy===

[[Image:taxonomy melanoma mod1.jpg|700px|center|thumb| '''Taxonomy''']]

==Intellectual property==

===Search strategy and concept===

Date of Search: 1836 to October 26, 2009
Database used: Micropatent - Include extensive full text and MPI-Inpadoc searches

===Search in Micropatent full text===

Micro patent full text search allow search in fulltext of US, EP, PCT, Great Britain, and German patent records as well as the front page of JP documents. US, EP, and DE are covered at first publication and when granted.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''Sr. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search reason'''
|align = "center" bgcolor = "#99CCFF"|'''Class Code (IPC,US,ECLA)'''
|align = "center" bgcolor = "#99CCFF"|'''Search quey'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|Specific classes of interferon AND melanoma keywords
|align = "center"|A61K003821<nowiki>*</nowiki> OR C07K014555 OR C07K001456 OR C07K014565 OR C07K001457 OR C07K014715G OR 4240854 OR 4242811 OR 42400141 OR 514889 OR 530351 OR 930142
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|576
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|Broad classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K003819 OR C07K001452 OR 4240851 OR 4240855 OR 4240856 OR 4240857 OR A61P003500
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|756
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|'''Final query'''
|align = "center" colspan = "4"|'''1 OR 2'''
|align = "center"|1019 records '''571 unique records'''
|-
|}

===Search in Micropatent MPI-INPADOC===

Micrpatent MPI-INPADOC search bibliographic data for 71 countries and legal status for 42. Only those patents were analyzed which have English title and/or abstract.

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''Sr. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''Search reason'''
|align = "center" bgcolor = "#99CCFF"|'''Class search'''
|align = "center" bgcolor = "#99CCFF"|'''Search quey'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Specific IPC classes of interferon AND melanoma keywords
|align = "center"|A61K03821 OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|174
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Broad IPC classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K03819 OR C07K01452 OR A61P03500
|align = "center"|(IFN<nowiki>*</nowiki> OR <nowiki>*</nowiki>IFN OR interferon<nowiki>*</nowiki> OR <nowiki>*</nowiki>interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|484
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Specific ECLA classes of interferon AND melanoma keywords
|align = "center"|A61K03821<nowiki>*</nowiki> OR C07K014555 OR C07K01456 OR C07K014565 OR C07K01457 OR C07K014715G
|align = "center"|(Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|102
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|Broad ECLA classes of interferon AND melanoma, interferon keywords
|align = "center"|A61K03819 OR C07K01452 OR A61P03500
|align = "center"|(IFN<nowiki>*</nowiki> OR <nowiki>*</nowiki>IFN OR interferon<nowiki>*</nowiki> OR <nowiki>*</nowiki>interferon OR huIFN) AND (Melanoma OR (Skin NEAR3 (cancer OR carcinoma OR tumor)) OR (Melanocyte<nowiki>*</nowiki> NEAR3 (cancer OR carcinoma OR tumor)))
|align = "center"|9
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center" colspan = "4"|'''Final query'''
|align = "center"|'''1 OR 2 OR 3 OR 4'''
|align = "center"|587 hits '''232 unique records'''
|-
|}

===Class codes used in searches===

* '''Relevant IPC classes'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''IPC'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|align = "center" bgcolor = "#C0C0C0"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing peptides Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|A61P003500
|align = "center"|Therapeutic activity of chemical compounds or medicinal preparations -antineoplastic agents
|align = "center"|Broad
|-
|}

* '''Relevant ECLA classes'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''ECLA'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|align = "center" bgcolor = "#C0C0C0"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|A61K38/21A
|align = "center"|Medicinal preparations containing IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|A61K38/21B
|align = "center"|Medicinal preparations containing IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|A61K38/21C
|align = "center"|Medicinal preparations containing IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''9'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''10'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C0"|'''11'''
|align = "center"|C07K014715G
|align = "center"|Receptors; Cell surface antigens; Cell surface determinants - for interferons -
|align = "center"|Specific
|-
|}

* '''Relevant US classes'''

{|border="2" cellspacing="0" cellpadding="4" width="50%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''US class'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center" bgcolor = "#C0C0C0"|'''Class Code'''
|align = "center" bgcolor = "#C0C0C0"|'''Class definition'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|4240854
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - this subclass provides for patents which broadly claim interferon or a method of treatment of interferon where the classification of the interferon as alpha, beta or gamma interferon is impossible
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|4242811
|align = "center"| DRUG, BIO-AFFCTING AND BODY TREATING COMPOSITIONS - Virus (e.g., interferon-inducing virus, etc.)
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|42400141
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|514889
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - INTERFERON INDUCER
|-
|align = "center" bgcolor = "#C0C0C0"|'''5'''
|align = "center"|530351
|align = "center"| CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF - Lymphokines, e.g., interferons, interlukins, etc.
|-
|align = "center" bgcolor = "#C0C0C0"|'''6'''
|align = "center"|930142
|align = "center"|PEPTIDE OR PROTEIN SEQUENCE - Interferon
|-
|align = "center" bgcolor = "#C0C0C0"|'''7'''
|align = "center"|4240851
|align = "center"|LYMPHOKINE - Included in this and the indented subclasses interferon, interleukin and macrophage factors (monokines)
|-
|align = "center" bgcolor = "#C0C0C0"|'''8'''
|align = "center"|4240855
|align = "center"|Gamma or immune: This subclass is indented under subclass 85.4. Subject matter in which the interferon is gamma or immune interferon.
|-
|align = "center" bgcolor = "#C0C0C0"|'''9'''
|align = "center"|4240856
|align = "center"|Subject matter in which the interferon is beta or fibroblast interferon.
|-
|align = "center" bgcolor = "#C0C0C0"|'''10'''
|align = "center"|4240857
|align = "center"|Subject matter in which the interferon is alpha or leukocyte interferon.
|-
|}

===Search in Japanese database===

Database: IPDL (Industrial property digital library), Japan

Date of search: 1900/01/01 to 2009/10/26

'''Total patents: 846 (Relevancy ~10%)'''

* '''F-Terms and theme used in search'''

{|border="2" cellspacing="0" cellpadding="4" width="75%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''Japanese F-term search'''
|align = "center" bgcolor = "#99CCFF"|'''Definition'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''Sr. No.'''
|align = "center"|'''F- Term theme'''
|align = "center"|'''4H045'''
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereo
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|F-term
|align = "center"|DA15
|align = "center"|Peptide or protein characterised by function - Interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|F-term
|align = "center"|DA16
|align = "center"|Alpha-interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|F-term
|align = "center"|DA17
|align = "center"|Beta-interferons
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|F-term
|align = "center"|DA18
|align = "center"|Gamma-interferons
|-
|}

==Sample patents==

{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#C0C0C0"|'''S.No.'''
|align = "center" bgcolor = "#99CCFF"|'''Patent/Publication No.'''
|align = "center" bgcolor = "#99CCFF"|'''Date of Publication'''
|align = "center" bgcolor = "#99CCFF"|'''Assignee / Applicant'''
|align = "center" bgcolor = "#99CCFF"|'''Inventor(s)'''
|align = "center" bgcolor = "#99CCFF"|'''Title'''
|align = "center" bgcolor = "#C0C0C0"|'''Dolcera Summary'''
|-
|align = "center" bgcolor = "#C0C0C0"|'''1'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=20051027&CC=US&NR=2005238621A1&KC=A1 US7482014B2]
|align = "center"|1/27/2009
|align = "center"|Schering Corporation
|align = "center"|Rybak, Mary Ellen and Rose, Esther Helen
|align = "center"|Melanoma therapy
|align = "center"|The invention relates to a method of treating a patient having Stage IIB or Stage III melanoma which has been surgically removed. A first dose of 6.0 micrograms/kg of pegylated interferon alpha-2b once a week for eight weeks, and then administering to the patient a second dose of 3.0 or less micrograms/kg of pegylated interferon alpha-2b once a week for the remainder of a five year treatment period.
|-
|align = "center" bgcolor = "#C0C0C0"|'''2'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19991207&CC=US&NR=5997858A&KC=A US5997858A]
|align = "center"|12/7/1999
|align = "center"|Pharma Pacific Pty Ltd.
|align = "center"|Tovey, Michael Gerard and Kaido, Thomas James
|align = "center"|Stimulation of host defense mechanisms against tumors
|align = "center"|A method for treating multiple myeloma, hairy cell leukemia, malignant melanoma, brain tumors etc. by administering a therapeutically effective amount of an interferon (1500 IU to about 20×106 IU for a 70 kg man per day) via oromucosal contact.
|-
|align = "center" bgcolor = "#C0C0C0"|'''3'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19881026&CC=EP&NR=0288055A1&KC=A1 EP288055A1]
|align = "center"|10/26/1988
|align = "center"|MERRELL DOW PHARMACEUTICALS INC.
|align = "center"|Sunkara, Sai P.
|align = "center"|Use of ODC inhibitors, dacarbazine, and interferon, in the treatment of malignant melanoma
|align = "center"|A combinational therapy containing an ornithine decarboxylase inhibitor, Interferon and Dacarbazine for simultaneous, separate or sequential use in treating rapidly-proliferating cell-growth disease such as melanoma.
|-
|align = "center" bgcolor = "#C0C0C0"|'''4'''
|align = "center"|[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19871014&CC=EP&NR=0241242A1&KC=A1 EP241242A1]
|align = "center"|10/14/1987
|align = "center"|CETUS ONCOLOGY CORPORATION
|align = "center"|Rudolph, Alfred
|align = "center"|The use of interferon-beta and interleukin-2 for combination therapy and compositions therefor
|align = "center"|A composition comprising of a mixture of lFN- beta and IL-2 for administration to human patients for therapeutic or prophylactic treatment of cancer such as colon cancer, melanoma, renal cell cancer, lung cancer.
|-
|}

Main Page

2009-10-30T11:35:51Z

Anand.shukla: /* Intellectual Property (IP) Services */

__NOTOC__
===1. [[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]===
===2. [[#Business and Information Research Services|Business and Information Research Services]]===
===3. [[#Dolcera Technology Platform|Dolcera Technology Platform]]===

== Intellectual Property (IP) Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey;width:50%" valign = "top" |
===Life Sciences and Chemistry===
! style="background:lightgrey;width:50%" valign = "top" |
===Technology===
|-
| valign = "top" |
=== Landscape reports ===
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])
* [[Inflammation and cardiovascular drugs]]
* [[Hormone Sensitive Lipase]]
* [[RNA Interference]]
* [[RNAi Database sample wiki]]
* [[Choline Bitartarate]]
* [[Non-wovens]]
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])
* [[Ureteral Stent]]
* [[Smart miniature drug delivery systems]]
* [[Silicone Hydrogel contact lens]]
* [[Biofuels database sample wiki]]
* [[SC Johnson]]
| valign = "top" |

=== Landscape Reports ===
* [[Hybrid Electric Vehicle Battery System]]
* [[Supply Chain RFID Applications]]
* [[Insurance sector]]
* [[CDMA Basics]]
* [[Quality of Service on CDMA platforms]]
* [[OLED - Organic Light Emitting Diode]]
* [[Carbon Nanotubes (CNT)]]
* [[Metallic and Ceramic construction materials]]
* [[Transactional memory]]
* [[Invalidation Search on a patent in the semiconductors space]]
|-
| valign = "top" |

===STN Search Reports===
* [[Markush Search Report]]

=== Dashboard ===
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live]
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]])
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]
| valign = "top" |

=== Dashboard ===
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]
** [[Automotive Dashboard Screenshots|Screenshots only]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live]
** [[WiMAX Dashboard Screenshots|Screenshots only]]
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]
|-
| valign = "top" |

=== Prior Art / Invalidation / FTO Search ===
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]
* [[Markush Structure Search Sample]]
==== Study: In re Bilski Impact ====
* [[In re Bilski Impact assessed from US PAIR Information]]
| valign = "top" |

=== Prior Art / Invalidation / FTO Search ===
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Map Sample]
|-
|}

===Clinical Trial Database===
*[[Clinical Trial Database]]

== Business and Information Research Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey" valign=top width=50%|
===Life Sciences and Chemistry===
! style="background:lightgrey" valign=top width=50%|
===Technology===
|-
| valign=top |
* [[Diabetes products and services]]
* [[Osteoporosis]]
* [[Oral Diabetes Drugs]]
* [[Ureteral Stent]]
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]
* [[OTC products for acne treatment]]
* [[Botox - from Medical Procedure to Household Word]]
| valign=top |
* [[4G wireless technology developments]]
* [[HDTV in the US]]
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]
* [[Web video]]
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])
* [[Virtualization]]
* [[Cloud Computing]]
* [[Estimation of liquid carrying vehicles in USA]]
* [[A market study on Hybrid vehicles and the concept of V2G]]
|-
! style="background:lightgrey" valign=top colspan=2 |

===Finance===
|-
| valign=top colspan=2 |
* [[Innovative personal finance products]]
* [[Life Insurance Industry in US]]
|}

== Dolcera Technology Platform ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
| align = "top" |
==== IP and Products dashboard ====
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard]
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]

==== Patent-pathway mapping ====
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]
==== Sequence dashboard ====
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]

==== Design analysis ====
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]

==== Innovation explorer ====
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]
==== KPort ====
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]

|-
|}

=== Dolcera Offerings summary ===
* [[Dolcera Offerings|Dolcera offerings summary]]

=== [[Technology Support]] ===

==Like any of these sample reports?==
 '''These are sample reports with brief analysis''' 
'''Dolcera can provide a comprehensive report customized to your needs'''
{|border="2" cellspacing="0" cellpadding="4" align="center" "
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com Buy the customized report from Dolcera]'''
|-
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
|-
|}
 

----
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"
|-
! style="background:lightgrey" | Contact Dolcera
|-
! style="background:lightgrey" | Samir Raiyani
|-
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]
|-
| '''Phone''': +1-650-269-7952, +91-40-2355-3493
|}

Main Page

2009-10-30T11:35:25Z

Anand.shukla: /* Intellectual Property (IP) Services */

__NOTOC__
===1. [[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]===
===2. [[#Business and Information Research Services|Business and Information Research Services]]===
===3. [[#Dolcera Technology Platform|Dolcera Technology Platform]]===

== Intellectual Property (IP) Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey;width:50%" valign = "top" |
===Life Sciences and Chemistry===
! style="background:lightgrey;width:50%" valign = "top" |
===Technology===
|-
| valign = "top" |
=== Landscape reports ===
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])
* [[Inflammation and cardiovascular drugs]]
* [[Hormone Sensitive Lipase]]
* [[RNA Interference]]
* [[RNAi Database sample wiki]]
* [[Choline Bitartarate]]
* [[Non-wovens]]
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])
* [[Ureteral Stent]]
* [[Smart miniature drug delivery systems]]
* [[Silicone Hydrogel contact lens]]
* [[Biofuels database sample wiki]]
* [[SC Johnson]]
| valign = "top" |

=== Landscape Reports ===
* [[Hybrid Electric Vehicle Battery System]]
* [[Supply Chain RFID Applications]]
* [[Insurance sector]]
* [[CDMA Basics]]
* [[Quality of Service on CDMA platforms]]
* [[OLED - Organic Light Emitting Diode]]
* [[Carbon Nanotubes (CNT)]]
* [[Metallic and Ceramic construction materials]]
* [[Transactional memory]]
* [[Invalidation Search on a patent in the semiconductors space]]
|-
| valign = "top" |

=== ===

===STN Search Reports===
* [[Markush Search Report]]

=== Dashboard ===
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live]
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]])
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]
| valign = "top" |

=== Dashboard ===
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]
** [[Automotive Dashboard Screenshots|Screenshots only]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live]
** [[WiMAX Dashboard Screenshots|Screenshots only]]
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]
|-
| valign = "top" |

=== Prior Art / Invalidation / FTO Search ===
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]
* [[Markush Structure Search Sample]]
==== Study: In re Bilski Impact ====
* [[In re Bilski Impact assessed from US PAIR Information]]
| valign = "top" |

=== Prior Art / Invalidation / FTO Search ===
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Map Sample]
|-
|}

===Clinical Trial Database===
*[[Clinical Trial Database]]

== Business and Information Research Services ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
! style="background:lightgrey" valign=top width=50%|
===Life Sciences and Chemistry===
! style="background:lightgrey" valign=top width=50%|
===Technology===
|-
| valign=top |
* [[Diabetes products and services]]
* [[Osteoporosis]]
* [[Oral Diabetes Drugs]]
* [[Ureteral Stent]]
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]
* [[OTC products for acne treatment]]
* [[Botox - from Medical Procedure to Household Word]]
| valign=top |
* [[4G wireless technology developments]]
* [[HDTV in the US]]
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]
* [[Web video]]
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])
* [[Virtualization]]
* [[Cloud Computing]]
* [[Estimation of liquid carrying vehicles in USA]]
* [[A market study on Hybrid vehicles and the concept of V2G]]
|-
! style="background:lightgrey" valign=top colspan=2 |

===Finance===
|-
| valign=top colspan=2 |
* [[Innovative personal finance products]]
* [[Life Insurance Industry in US]]
|}

== Dolcera Technology Platform ==
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"
|-
| align = "top" |
==== IP and Products dashboard ====
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard]
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]
* [[Legal Updates Demo|Legal updates dashboard]]
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]

==== Patent-pathway mapping ====
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]
==== Sequence dashboard ====
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]

==== Design analysis ====
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]

==== Innovation explorer ====
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]
==== KPort ====
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]

|-
|}

=== Dolcera Offerings summary ===
* [[Dolcera Offerings|Dolcera offerings summary]]

=== [[Technology Support]] ===

==Like any of these sample reports?==
 '''These are sample reports with brief analysis''' 
'''Dolcera can provide a comprehensive report customized to your needs'''
{|border="2" cellspacing="0" cellpadding="4" align="center" "
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com Buy the customized report from Dolcera]'''
|-
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]
|-
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]
|-
|}
 

----
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"
|-
! style="background:lightgrey" | Contact Dolcera
|-
! style="background:lightgrey" | Samir Raiyani
|-
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]
|-
| '''Phone''': +1-650-269-7952, +91-40-2355-3493
|}

Diamond Tipped Indenting Tool

2009-10-29T15:33:37Z

Anand.shukla: /* Utility */

== Agenda ==

* '''To introduce and explain the benefits of the patented technology developed by Pratt & Whitney.'''

* '''To find out interest of the prospects in acquiring the technology on a licensed basis from Pratt & Whitney.'''

== About Dolcera ==

[[Image:dolcera logo image.jpg|right]]
* Dolcera is an international services firm specializing in intellectual property and market research services. Our clientele includes several fortune 500 companies and global 100 companies. For more information please visit: [http://dolcera.com/ www.dolcera.com]

* We at Dolcera are partnering with Pratt & whitney to out-license their highly durable diamond indenting tool technology.

== About Pratt & Whitney ==

[[Image:pratt logo.jpg|right]]
* Pratt & Whitney is one of the largest aircraft engine manufacturers in the world with a sales revenue of more than $12 Bn and spends more than $250 Mn in research & development.

* Cutting edge R&D with over a 1000 patents.

* Has always been at the forefront of technologies for turbine, rocket, reciprocating engines, power systems, etc.

== Utility ==
[[Image:Indenting tool image1.jpg|thumb|500px|Indenting tool]]
* A Tool using this technology has a diamond at a specified precise orientation affixed to the tip of the shank of the machine Enabling markings on various metal surfaces for
* Identification purposes
* Surface treatment
* Surface condition
* The point of the tool strikes the surface of metal and on impact creates a cold-formed indentation or mark.
 
 
 
 
 
 
 

== Schematic Representation - Indenting Tool ==
[[Image:Schematic Representation-indenter.jpg]]

== Graphical Representation - Tool tip ==
[[Image:Graphical Representation indenting tool.jpg|thumb|right|500px]]

* '''Stereographic projection triangle for the diamond crystal'''
Represents a 3D orientation spread out on a 2D plane.
Figure depicts the orientation of the diamond tip.
It Shows the axis of orientation of the diamond crystal w.r.t three standard orientations of the crystal marked by the 3 vertices.The pole of the crystal should lie within the dotted circle to achieve the super wear resistance orientation

 
 
 
 
 
 
 
 
 
 

== Importance of the orientation ==

* Diamond crystals are anisotropic
* Their mechanical and physical properties vary with their crystallographic orientation
* The orientation of the crystal governs its strength and wear resistance
* This particular '''super wear-resistant orientation''' has been discovered and patented by Pratt and Whitney.

== Limitations of other technologies ==

* Carbide and non-oriented diamond indenters have problems such as

# Wear and tear of tool head
# Replacement costs

== Advantages of this tool ==

* '''Economical'''
# Low replacement costs because of increased tool life (up too 100 times that of carbide tools)
# Reduced cost per mark

* '''Quality'''
# Better reading of 2D markings
# Improved marking reliability and quality

* '''Physical'''
# Improved wear resistance
# Less force required to obtain indention depth

== Applications ==

* Aero & Industrial Gas Turbines
* Railway
* Machineries
* Weapon markings
* Punches and Dies
* Cables and Wires
* Weapon markings
* Any metal equipment

== Legal Status ==
[[Image:Legal status indenter.jpg]]

2009-10-29T10:02:33Z

Anand.shukla:

Diamond Tipped Indenting Tool

2009-10-29T10:00:40Z

Anand.shukla: /* Utility */

== Agenda ==

* '''To introduce and explain the benefits of the patented technology developed by Pratt & Whitney.'''

* '''To find out interest of the prospects in acquiring the technology on a licensed basis from Pratt & Whitney.'''

== About Dolcera ==

[[Image:dolcera logo image.jpg|right]]
* Dolcera is an international services firm specializing in intellectual property and market research services. Our clientele includes several fortune 500 companies and global 100 companies. For more information please visit: [http://dolcera.com/ www.dolcera.com]

* We at Dolcera are partnering with Pratt & whitney to out-license their green technology to replace Ni-Cd coatings used for finishing purposes.

== About Pratt & Whitney ==

[[Image:pratt logo.jpg|right]]
* Pratt & Whitney is one of the largest aircraft engine manufacturers in the world with a sales revenue of more than $12 Bn and spends more than $250 Mn in research & development.

* Cutting edge R&D with over a 1000 patents.

* Has always been at the forefront of technologies for turbine, rocket, reciprocating engines, power systems, etc.

== Utility ==
[[Image:Indenting tool image.jpg|thumb|500px|right]]
* A Tool using this technology has a diamond at a specified precise orientation affixed to the tip of the shank of the machine Enabling markings on various metal surfaces for
* Identification purposes
* Surface treatment
* Surface condition
* The point of the tool strikes the surface of metal and on impact creates a cold-formed indentation or mark.

== Schematic Representation - Indenting Tool ==
[[Image:Schematic Representation-indenter.jpg]]

== Graphical Representation - Tool tip ==
[[Image:Graphical Representation indenting tool.jpg|thumb|right|500px]]

* '''Stereographic projection triangle for the diamond crystal'''
Represents a 3D orientation spread out on a 2D plane.
Figure depicts the orientation of the diamond tip.
It Shows the axis of orientation of the diamond crystal w.r.t three standard orientations of the crystal marked by the 3 vertices.The pole of the crystal should lie within the dotted circle to achieve the super wear resistance orientation

 
 
 
 
 
 
 
 
 
 

== Importance of the orientation ==

* Diamond crystals are anisotropic
* Their mechanical and physical properties vary with their crystallographic orientation
* The orientation of the crystal governs its strength and wear resistance
* This particular '''super wear-resistant orientation''' has been discovered and patented by Pratt and Whitney.

== Limitations of other technologies ==

* Carbide and non-oriented diamond indenters have problems such as

# Wear and tear of tool head
# Replacement costs

== Advantages of this tool ==

* '''Economical'''
# Low replacement costs because of increased tool life (up too 100 times that of carbide tools)
# Reduced cost per mark

* '''Quality'''
# Better reading of 2D markings
# Improved marking reliability and quality

* '''Physical'''
# Improved wear resistance
# Less force required to obtain indention depth

== Applications ==

* Aero & Industrial Gas Turbines
* Railway
* Machineries
* Weapon markings
* Punches and Dies
* Cables and Wires
* Weapon markings
* Any metal equipment

== Legal Status ==
[[Image:Legal status indenter.jpg]]

File:Legal status indenter.jpg

2009-10-29T09:59:15Z

Anand.shukla:

Diamond Tipped Indenting Tool

2009-10-29T09:59:02Z

Anand.shukla: /* Applications */

== Agenda ==

* '''To introduce and explain the benefits of the patented technology developed by Pratt & Whitney.'''

* '''To find out interest of the prospects in acquiring the technology on a licensed basis from Pratt & Whitney.'''

== About Dolcera ==

[[Image:dolcera logo image.jpg|right]]
* Dolcera is an international services firm specializing in intellectual property and market research services. Our clientele includes several fortune 500 companies and global 100 companies. For more information please visit: [http://dolcera.com/ www.dolcera.com]

* We at Dolcera are partnering with Pratt & whitney to out-license their green technology to replace Ni-Cd coatings used for finishing purposes.

== About Pratt & Whitney ==

[[Image:pratt logo.jpg|right]]
* Pratt & Whitney is one of the largest aircraft engine manufacturers in the world with a sales revenue of more than $12 Bn and spends more than $250 Mn in research & development.

* Cutting edge R&D with over a 1000 patents.

* Has always been at the forefront of technologies for turbine, rocket, reciprocating engines, power systems, etc.

== Utility ==

* A Tool using this technology has a diamond at a specified precise orientation affixed to the tip of the shank of the machine Enabling markings on various metal surfaces for
* Identification purposes
* Surface treatment
* Surface condition
* The point of the tool strikes the surface of metal and on impact creates a cold-formed indentation or mark.

== Schematic Representation - Indenting Tool ==
[[Image:Schematic Representation-indenter.jpg]]

== Graphical Representation - Tool tip ==
[[Image:Graphical Representation indenting tool.jpg|thumb|right|500px]]

* '''Stereographic projection triangle for the diamond crystal'''
Represents a 3D orientation spread out on a 2D plane.
Figure depicts the orientation of the diamond tip.
It Shows the axis of orientation of the diamond crystal w.r.t three standard orientations of the crystal marked by the 3 vertices.The pole of the crystal should lie within the dotted circle to achieve the super wear resistance orientation

 
 
 
 
 
 
 
 
 
 

== Importance of the orientation ==

* Diamond crystals are anisotropic
* Their mechanical and physical properties vary with their crystallographic orientation
* The orientation of the crystal governs its strength and wear resistance
* This particular '''super wear-resistant orientation''' has been discovered and patented by Pratt and Whitney.

== Limitations of other technologies ==

* Carbide and non-oriented diamond indenters have problems such as

# Wear and tear of tool head
# Replacement costs

== Advantages of this tool ==

* '''Economical'''
# Low replacement costs because of increased tool life (up too 100 times that of carbide tools)
# Reduced cost per mark

* '''Quality'''
# Better reading of 2D markings
# Improved marking reliability and quality

* '''Physical'''
# Improved wear resistance
# Less force required to obtain indention depth

== Applications ==

* Aero & Industrial Gas Turbines
* Railway
* Machineries
* Weapon markings
* Punches and Dies
* Cables and Wires
* Weapon markings
* Any metal equipment

== Legal Status ==
[[Image:Legal status indenter.jpg]]